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Abstract
Globular glial tauopathy (GGT) is a progressive neurodegenerative disease involving the grey matter and white matter (WM) 
and characterized by neuronal deposition of hyper-phosphorylated, abnormally conformed, truncated, oligomeric 4Rtau in 
neurons and in glial cells forming typical globular astrocyte and oligodendrocyte inclusions (GAIs and GOIs, respectively) 
and coiled bodies. Present studies centre on four genetic GGT cases from two unrelated families bearing the P301T mutation 
in MAPT and one case of sporadic GGT (sGGT) and one case of GGT linked to MAPT K317M mutation, for comparative 
purposes. Clinical and neuropathological manifestations and biochemical profiles of phospho-tau are subjected to individual 
variations in patients carrying the same mutation, even in carriers of the same family, independently of the age of onset, 
gender, and duration of the disease. Immunohistochemistry, western blotting, transcriptomic, proteomics and phosphoprot-
eomics, and intra-cerebral inoculation of brain homogenates to wild-type (WT) mice were the methods employed. In GGT 
cases linked to MAPT P301T mutation, astrocyte markers GFAP, ALDH1L1, YKL40 mRNA and protein, GJA1 mRNA, and 
AQ4 protein are significantly increased; glutamate transporter GLT1 (EAAT2) and glucose transporter (SLC2A1) decreased; 
mitochondrial pyruvate carrier 1 (MPC1) increased, and mitochondrial uncoupling protein 5 (UCP5) almost absent in GAIs 
in frontal cortex (FC). Expression of oligodendrocyte markers OLIG1 and OLIG2 mRNA, and myelin-related genes MBP, 
PLP1, CNP, MAG, MAL, MOG, and MOBP are significantly decreased in WM; CNPase, PLP1, and MBP antibodies reveal 
reduction and disruption of myelinated fibres; and SMI31 antibodies mark axonal damage in the WM. Altered expression of 
AQ4, GLUC-t, and GLT-1 is also observed in sGGT and in GGT linked to MAPT K317M mutation. These alterations point 
to primary astrogliopathy and oligodendrogliopathy in GGT. In addition, GGT linked to MAPT P301T mutation proteotypes 
unveil a proteostatic imbalance due to widespread (phospho)proteomic dearrangement in the FC and WM, triggering a 
disruption of neuron projection morphogenesis and synaptic transmission. Identification of hyper-phosphorylation of varie-
gated proteins calls into question the concept of phospho-tau-only alteration in the pathogenesis of GGT. Finally, unilateral 
inoculation of sarkosyl-insoluble fractions of GGT homogenates from GGT linked to MAPT P301T, sGGT, and GGT linked 
to MAPT K317M mutation in the hippocampus, corpus callosum, or caudate/putamen in wild-type mice produces seeding, 
and time- and region-dependent spreading of phosphorylated, non-oligomeric, and non-truncated 4Rtau and 3Rtau, without 
GAIs and GOIs but only of coiled bodies. These experiments prove that host tau strains are important in the modulation of 
cellular vulnerability and phenotypes of phospho-tau aggregates.
Keywords Globular glial tauopathy · Tau · Astrogliopathy · Oligodendrogliopathy · Phosphoproteome · Seeding and 
spreading
Introduction
Globular glial tauopathy (GGT) identifies a group of 
neurodegenerative diseases with abnormal accumulation 
of phospho-tau in neurons and phospho-tau-containing 
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globular glial inclusions (GGIs) in astrocytes and oli-
godendrocytes [1, 3, 7, 45, 63, 70]. GGIs in astrocytes 
(GAIs) differ from tufted astrocytes, astrocytic plaques, 
thorn-shaped astrocytes, and fibrillar astrocytes containing 
phospho-tau in other tauopathies; however, tufted astro-
cytes and, rarely, astrocytic plaques can be found in GGTs. 
Globular inclusions in oligodendrocytes (GOIs) differ 
from coiled bodies, although both types of oligodendro-
glial inclusions may co-exist in GGT. Western blotting of 
sarkosyl-insoluble fractions reveals a typical 4Rtau band 
pattern consisting of two bands of 68 kDa and 64 kDa and 
several lower bands of about 35 kDa of phosphorylated 
tau [3, 7, 38, 45].
The majority of GGTs are sporadic [1], but a few famil-
ial cases have been reported linked to different mutations 
in the microtubule-associated protein tau gene (MAPT): 
N296H in exon 10 [62], R5H in exon 1 [56], K317M in 
exon 11 [40, 135], K317N in exon 11 [111], P301L in 
exon 10 [10, 44, 112], and IVS10 + 16 [44]. Recently, we 
have reported five new cases of familial GGT from two 
unrelated pedigrees bearing the P301T mutation in MAPT 
[28]. A typical 4Rtau band pattern consisting of two bands 
of 68 kDa and 64 kDa, and several lower bands of about 
35 kDa, is also found in familial GGTs [28, 111, 135]. 
GGT has been classified according to three subtypes [1]. 
Type I has predominant frontal symptoms and pathology, 
abundant GOIs, and scarce coiled bodies and GAIs; type 
III is manifested by severe involvement of the frontal cor-
tex, motor cortex, temporal cortex, and anterior horn of the 
spinal cord, and presents abundant GAIs in the cerebral 
cortex, and GOIs and colied bodies in the white matter; 
and type II has severe involvement of the motor cortex and 
pyramidal tracts, abundant GOIs and coiled bodies in the 
white matter but low numbers of GAIs in the cerebral cor-
tex [1]. Involvement of the frontal white matter is usually 
severe in types I and III, and involvement of the substantia 
nigra occurs in types II and III [3].
Beyond the clinical manifestations and typical neuro-
pathological hallmarks, little is known about molecular 
alterations in GGT and possible implications in the patho-
genesis of the disease. Moreover, although GAIs and GOIs 
are typical of GGT, nothing is known about the functional 
alterations linked to the pathology of astrocytes and oligo-
dendrocytes. Recent studies have shown the seeding capac-
ity of GGT homogenates in vivo and in vitro [13, 36, 41]. 
However, little attention has been paid to the characteristics 
of tau deposits linked to the host tau.
Our hypotheses are that (a) astrocytes and oligodendro-
cytes are principal targets and dysfunctional players in the 
pathogenesis of GGT; (b) GGT, like other neurodegenerative 
diseases with hyper-phosphorylated tau deposition, is a more 
generalized disease with hyper-phosphorylation of a large 
number of proteins in addition to tau; and (c) inoculation in 
wild-type (WT) mice of abnormal mutant tau from human 
GGT brain homogenates has the capacity to recruit murine 
tau to generate seeding and spreading largely dependent on 
the characteristics of host tau.
Therefore, the present study is geared to learning about (i) 
characterization of phospho-tau species in GGT; (ii) molecu-
lar alterations in astrocytes and oligodendrocytes, (iii) pro-
teostatic dearrangements in addition to tau in the brain of 
GGT cases, and (iv) capacities of seeding and spreading for 
abnormal tau from GGT homogenates containing human 
mutant tau after inoculation in the brain of WT mice, and 
characterization of inclusions in glial cells.
For these purposes, we focused the study on recently 
reported genetic GGT cases from two unrelated pedigrees 
bearing the P301T mutation in MAPT [28]. For comparative 
purposes, we also analysed one sporadic GGT presenting 
with primary progressive aphasia [case 1, 38], and another 
genetic GGT case manifested with frontotemporal dementia, 
parkinsonism, and motor neuron disease linked to K317M 
mutation in MAPT [135].
Materials and methods
Familial GGT linked to P301T mutation in MAPT
Patients belonged to two apparently unrelated pedigrees 
from a small region of the north of Spain. Case 1 belongs 
to pedigree 1; and cases 2, 3 and 4, two brothers and one 
sister from seven siblings, to pedigree 2. Patients bore the 
same P301T mutation in the MAPT gene; detailed clinical 
manifestations are reported in the original description [28].
Case 1
The patient was a man aged 45 years with progressive gait 
disturbance. The neurological examination showed pyrami-
dal syndrome, and a diagnosis of primary lateral sclerosis 
was initially established. He developed cognitive decline, 
with non-fluent speech, paresis of vertical and horizontal 
gaze movements, axial rigidity, and asymmetric tetraparesis 
with severe spasticity and dystonic postures. He died at the 
age of 49 with a clinical diagnosis of progressive supranu-
clear palsy plus primary lateral sclerosis. He was an only 
child; his mother died at the age of 70 years with a clinical 
diagnosis of probable corticobasal degeneration. His grand-
father had suffered from dementia and died at the age of 53.
Case 2
The patient was a 49-year-old man who had suffered from 
gait instability, loss of motor coordination of the right hand, 
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alien hand, myoclonus, and dystonic movements in the right 
extremities. This was followed by cognitive impairment and 
frontotemporal dementia. The clinical diagnosis was corti-
cobasal syndrome. He died at the age of 55.
Case 3
The patient was a 43-year-old man with a short history of 
speech difficulties, rigidity, and bradikynesia in the right arm 
and leg, and alien hand, which were accompanied by aggres-
sive behaviour and cognitive decline. The clinical diagnosis 
was corticobasal syndrome. He died at the age of 47.
Case 4
The patient was a woman aged 55 who suffered from pro-
gressive apathy, anhedonia, and mood disorder progressing 
to stereotypic motor behaviour and dementia. The clinical 
diagnosis was frontotemporal dementia. She died at the age 
of 61.
The mother, one aunt, and two uncles of seven siblings, 
as well as the grandmother, had suffered from a neurological 
disease with variable clinical symptoms and predominant 
cognitive decline.
Other GGT cases: sporadic GGT and familial GGT 
linked to MAPT K317M mutation
Sporadic GGT (sGGT)
The patient was a 66-year-old right-handed woman with pri-
mary progressive aphasia. The cerebral magnetic resonance 
imaging (MRI) demonstrated cortical atrophy of the right 
perisylvian region and the left temporal lobe, together with 
hyperintense periventricular signals in the white matter. This 
was followed by buco-lingual apraxia, spasmodic laughter, 
difficulty in swallowing, and deterioration of cognitive func-
tions. The patient progressively lost mobility and suffered 
from cognitive deterioration, until death at the age of 81, 
12 years after the beginning of aphasia. Additional clinical 
details can be found in [38], case 1.
Familial GGT linked to MAPT K317M mutation
The patient was a 57-year-old woman suffering from dys-
arthria, bradykinesia, parkinsonism, pyramidal syndrome, 
slowing of ocular saccades, ideomotor apraxia, mutism, 
echolalia, and mirror movements, who died 11 years after 
the initiation of symptoms. One brother was affected by the 
same disease. The genetic study of a post-mortem sample of 
the cerebral cortex identified a K317M mutation in MAPT. 
Further details are described in [135], case I/III-21.
Control cases
Unrelated controls with no neurological symptoms and no 
brain lesions in the post-mortem neuropathological study (7 
men and 3 women; mean age: 67 ± 7 years) were processed 
and assessed in parallel.
The frontal cortex of one patient with Alzheimer’s disease 
(one man aged 78 years) Braak and Braak stage VI of neu-
rofibrillary tangle degeneration was used for comparison in 
western blotting studies.
Neuropathological study
Post-mortem human brains were obtained following the 
guidelines of the Spanish legislation on this matter (Real 
Decreto 2011/1716) and approval of the local ethics 
committees.
Immediately after removal of the brain from the skull, 
fresh samples from the frontal cortex and frontal white mat-
ter were frozen and stored at − 80 °C for biochemical studies. 
The rest of the brain was fixed in 4% buffered formalin, and 
selected samples of the brain and spinal cord were embed-
ded in paraffin. Tissue sections, 4 μm thick, were obtained 
with a sliding microtome. The sections were stained with 
haematoxylin and eosin, Klüver–Barrera, and Sudan black, 
or processed for immunohistochemistry. Additional tissue 
samples of the frontal cortex and underlying white matter 
were processed for Gallyas staining.
Immunohistochemistry
The sections were boiled in citrate buffer (20 min) to 
retrieve protein antigenicity. Endogenous peroxidases were 
blocked by incubation in 10% methanol–1%  H2O2 solution 
(15 min) followed by 3% normal horse serum solution. 
Then, the sections were incubated at 4 °C overnight with 
one of the primary antibodies listed in Table 1. Following 
incubation with the primary antibody, the sections were 
incubated with EnVision + system peroxidase (Dako, Agi-
lent Technologies, Santa Clara, CA, USA) for 30 min at 
room temperature. The peroxidase reaction was visualized 
with diaminobenzidine and  H2O2. Control of the immu-
nostaining included omission of the primary antibody; no 
signal was obtained following incubation with only the 
secondary antibody.
Quantification of blood vessels in sections processed for 
GLUC-t (glucose transporter) immunohistochemistry was 
carried out as follows: images were acquired at a magni-
fication 200× in five different areas of the frontal cortex 
in every case. The number of capillaries was expressed as 
the mean values ± SEM in area of 0.15  mm2. Quantification 
of GLUC-t-positive capillaries was performed using Fiji 
ImageJ software. Statistical analysis was performed using 
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GraphPad Prismv5 software. Results were analysed using 
the Student’s t test.
Double‑labelling immunofluorescence and confocal 
microscopy
De-waxed sections, 4 μm thick, were stained with a saturated 
solution of Sudan black B (Merck, Glostrup, DE) for 15 min 
to block the autofluorescence of lipofuscin granules present 
in cell bodies and then rinsed in 70% ethanol and washed 
in distilled water. The sections were incubated at 4 °C over-
night with combinations of primary antibodies AT8 or P-tau-
Thr181, and GFAP, YKL40, αB-crystallin, Tau-C3, MPC1 
(mitochondrial pyruvate carrier 1), UCP4 (mitochondrial 
uncoupling protein 4), UCP5 (mitochondrial uncoupling 
protein 4), histone H4 (di-methyl K9) and histone H3 (acetyl 
K12), and phosphorylate kinase p38 (p38-P Thr180-Tyr182). 
The characteristics of the antibodies are listed in Table 1. 
After washing, the sections were incubated with Alexa488 
or Alexa546 (1:400, Molecular Probes, Eugene, OR, USA) 
fluorescence secondary antibodies against the corresponding 
host species. Nuclei were stained with DRAQ5™ (dilution 
1:2000, BioStatus, Loughborough, UK). After washing, the 
sections were mounted in Immuno-Fluore mounting medium 
(ICN Biomedicals, Irvine, CA, USA), sealed, and dried 
Table 1  Characteristics of the antibodies used for immunohistochemistry and double-labelling immunofluorescence in human and mouse brain 
samples
Antibody Mono-/polyclonal Dilution Supplier Country
4Rtau Monoclonal 1:50 Merck-Millipore Billerica, MA, USA
3Rtau Monoclonal 1:800 Merck-Millipore Billerica, MA, USA
P-tauThr181 Rabbit polyclonal 1:50 Cell Signaling Danvers, MA, USA
P-tauSer422 Rabbit polyclonal 1:1000 Thermo Fisher Waltham, MA, USA
AT8 (Ser202/Thr205) Monoclonal 1:50 Innogenetics Ghent, BE
MC-1 (aa312-322) Monoclonal 1:50 Dr. Peter Davies USA
Tau-C3 (tr Asp421) Monoclonal 1:300 Abcam Cambridge, UK
tau-22 (oligomeric) Rabbit polyclonal 1:200 Merck-Millipore Billerica, MA, USA
NF-RT97 (NF 200 kDa) Monoclonal 1:50 Novocastra Newcastle, UK
SMI31 (phosphorylated neurofilament H) Monoclonal 1:300 Biolegend San Diego, CA, USA
NeuN Monoclonal 1:100 Merck-Millipore Billerica, MA, USA
GFAP: glial fibrillary acidic protein Rabbit polyclonal 1:500 Dako Glostrup, DK
Olig2 Rabbit polyclonal 1:500 Abcam Cambridge, UK
NG2 Rabbit polyclonal 1:200 Sigma-Aldrich, Merck Darmstadt, GE
Iba1 Rabbit polyclonal 1:1000 Wako Richmond, VA, USA
αB-crystallin Monoclonal 1:500 Novocastra-Leica Barcelona, Spain
YKL40 Rabbit polyclonal 1:200 Invitrogen Carlsbad, CA, USA
AQ4 Monoclonal 1:400 Sigma St Louis, Missouri, USA
GLT1 (glutamate transporter) EAAT2 Guinea pig 1:100 Merck-Millipore Billerica, MA, USA
MPC1: mitochondrial pyruvate carrier 1 Rabbit polyclonal 1:100 Cell Signaling Danvers, MA, USA
UCP4: mitochondrial uncoupling protein 4 Rabbit polyclonal 1:100 Abyntek Derio, BI, Spain
UCP5: mitochondrial uncoupling protein 5 Rabbit polyclonal 1:25 Novus Biologicals/Bionova Madrid, Spain
GLUC-t (glucose transporter) SLC2A1 Rabbit polyclonal 1:100 Abcam Cambridge, UK
CNPase Monoclonal 1:100 Sigma-Aldrich, Merck Darmstadt, GE
Myelin basic protein (MBP) Monoclonal 1:1000 Abcam Cambridge, UK
Proteolipid protein (PLP1) Monoclonal 1:100 LifeSpan Biosciences Seattle, WA, USA
Histone H3 (di-methyl K9) H3K9me2 Monoclonal 1:50 Abcam Cambridge, UK
Histone H4 (acetyl K12) H4K12ac Rabbit polyclonal 1:500 Abcam Cambridge, UK
p38-P Thr180-Tyr182 Rabbit polyclonal 1:100 Cell Signaling Danvers, MA, USA
β-Amyloid Monoclonal 1:50 Dako Glostrup, DK
α-Synuclein Rabbit polyclonal 1:500 Chemicon, Merck-Millipore Billerica, MA, USA
TDP-43 Rabbit polyclonal 1:200 Abcam Cambridge, UK
Ubiquitin Rabbit polyclonal 1:200 Dako Glostrup, DK
p62 Guinea pig polyclonal 1:100 Progen, RA Biopharm Darmstadt, GE
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overnight. Sections were examined with a Leica TCS-SL 
confocal microscope [40].
Co-localization of 2 proteins labelled with specific anti-
bodies and examined with the confocal microscope was 
assessed by counting cells expressing both antigens in rela-
tion to the number of cells stained with each one of the anti-
bodies in 5 selected fields per section at a magnification 
of 600 in every case. Quantitative studies were restricted 
to frontal cortex area 8 and underlying white matter. Val-
ues were expressed as the percentage in reference to the 
more abundant protein because the less abundant protein 
represented a subset of the former (e.g. percentage of P-tau-
Thr181-positive astrocytes containing tau-C3) [40].
Western blotting of sarkosyl‑insoluble fractions
Frozen samples of about 1 g from frontal cortex in every 
case, and frontal cortex and subcortical white matter sepa-
rately from case 1, were lysed in 10 volumes (w/v) with cold 
suspension buffer (10 mM Tris–HCl, pH 7.4, 0.8 M NaCl, 
1 mM EGTA) supplemented with 10% sucrose, protease, 
and phosphatase inhibitors (Roche, GE). The homogenates 
were first centrifuged at 20,000×g for 20 min (Ultracentri-
fuge Beckman with 70Ti rotor), and the supernatant (S1) 
was saved. The pellet was re-homogenized in 5 volumes of 
homogenization buffer and re-centrifuged at 20,000×g for 
20 min (Ultracentrifuge Beckman with 70Ti rotor). The two 
supernatants (S1 + S2) were then mixed and incubated with 
0.1% N-lauroylsarkosynate (sarkosyl) for 1 h at room tem-
perature while being shaken. Samples were then centrifuged 
at 100,000×g for 1 h (Ultracentrifuge Beckman with 70Ti 
rotor). Sarkosyl-insoluble pellets (P3) were re-suspended 
(0.2 ml/g) in 50 mM Tris–HCl (pH 7.4). Protein concen-
trations were quantified with the bicinchoninic acid assay 
(BCA) assay (Pierce, Waltham, MA, USA). Samples were 
mixed with loading sample buffer and heated at 95 °C for 
5 min. Sixty micrograms of protein was separated by elec-
trophoresis in SDS-PAGE gels and transferred to nitrocel-
lulose membranes (200 mA per membrane, 90 min). The 
membranes were blocked for 1 h at room temperature with 
5% non-fat milk in TBS containing 0.2% Tween and were 
then incubated with one of the primary antibodies: anti-tau 
Ser422 (diluted 1:1000), anti-4Rtau (diluted 1:1000), and 
anti-3Rtau (diluted 1:1000). After washing with TBS-T, 
blots were incubated with the appropriate secondary anti-
body (anti-mouse/anti-rabbit IgG conjugated with horserad-
ish peroxidase, diluted at 1:2000, DAKO, DE) for 45 min 
at room temperature. Immune complexes were revealed by 
incubating the membranes with chemiluminescence reagent 
(Amersham, GE Healthcare, Buckinghamshire, UK) [37]. 
Samples of the frontal cortex from one case with AD stage 
VI of Braak and Braak and one age-matched control without 
tau pathology were processed in the same way for compara-
tive purposes.
Sarkosyl-insoluble fractions of the frontal cortex and sub-
cortical white matter, and soluble fractions of the frontal 
cortex, were also used for inoculation in mice.
RNA purification, retro‑transcription reaction, and RT‑qPCR
RNA from frontal cortex and the white matter from the four 
familiar GGT cases linked to the MAPT P301T mutation 
was extracted following the instructions of the supplier 
(RNeasy Mini Kit,  Qiagen® GmbH, Hilden, Germany). 
Age-matched control cases (n = 10) without neurological or 
neuropathological lesions were processed in parallel. RNA 
integrity and 28S/18S ratios were determined with the Agi-
lent Bioanalyzer (Agilent Technologies Inc, Santa Clara, 
CA, USA) to assess RNA quality, and the RNA concentra-
tion was evaluated using a NanoDrop™ Spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). RIN values 
of GGT cases and controls were between 5.1 and 7.3. Com-
plementary DNA (cDNA) preparation used the High-Capac-
ity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA, USA) following the protocol provided by 
the supplier. Parallel reactions for each RNA sample were 
run in the absence of MultiScribe Reverse Transcriptase to 
assess the lack of contamination of genomic DNA. TaqMan 
RT-qPCR assays were performed in duplicate for each gene 
on cDNA samples in 384-well optical plates using an ABI 
Prism 7900 Sequence Detection system (Applied Biosys-
tems, Life Technologies, Waltham, MA, USA). For each 
10 μL TaqMan reaction, 4.5 μL cDNA was mixed with 
0.5 μL 20× TaqMan Gene Expression Assays and 5 μL of 2× 
TaqMan Universal PCR Master Mix (Applied Biosystems). 
Values of β-glucuronidase (GUS-β) were used as internal 
controls for normalization. TaqMan probes and references 
are listed in Table 2. The parameters of the reactions were 
50 °C for 2 min, 95 °C for 10 min, and 40 cycles of 95 °C 
for 15 s and 60 °C for 1 min. Finally, capture of all TaqMan 
PCR data used the Sequence Detection Software (SDS 
version 2.2.2, Applied Biosystems). For the data analysis, 
threshold cycle (CT) values for each sample were processed 
to obtain the double delta CT (ΔΔCT) values. First, delta CT 
(ΔCT) values were calculated as the normalized CT values 
of each target gene in relation to the CT of endogenous con-
trols GUS-β. Then, ΔΔCT values were obtained from the 
ΔCT of each sample minus the mean ΔCT of the population 
of control samples. Results were analysed using Student’s 
t test [4].
Neuroanatomical proteomics
Frontal cortex and underlying white matter specimens 
derived from the same control and GGT cases linked to 
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MAPT P301T mutation were homogenized separately in 
lysis buffer containing 7 M urea, 2 M thiourea, 4% (w/v), 
and 50 mM DTT supplemented with protease and phos-
phatase inhibitors. The homogenates were spun down at 
100,000×g for 1 h at 15 °C. After protein precipitation, pro-
tein concentration in the supernatants was measured with the 
Bradford assay kit (Biorad).
Protein digestion and peptide iTRAQ labelling
An iTRAQ (isobaric Tags for Relative and Absolute 
Quantitation)-based quantitative proteomic analysis was 
performed for frontal cortex and white matter as previously 
described [72, 136]. iTRAQ labelling of each sample was 
performed according to the manufacturer’s protocol (Sciex). 
Briefly, equal amounts of protein (100 μg) from each sample 
were reduced with 50 mM tris (2-carboxyethyl) phosphine 
(TCEP) at 60 °C for 1 h. Cysteine residues were alkylated 
with 200 mM methyl methanethiosulfonate (MMTS) at room 
temperature for 15 min. Protein enzymatic cleavage was car-
ried out with trypsin (Promega; 1:20, w/w) at 37 °C for 16 h. 
For both iTRAQ experiments, each tryptic digest was labelled 
with one isobaric amine-reactive tag as follows: Tag113, con-
trol-1; Tag114, control-2; Tag115, control-3; Tag116, con-
trol-4; Tag117, GGT-1; Tag118, GGT-2; Tag119, GGT-3; 
Tag121, GGT-4. After 2 h incubation, the sets of frontal cor-
tex- and white matter-labelled samples were independently 
pooled and evaporated in a vacuum centrifuge.
Phosphopeptide enrichment and LC–MS/MS
The enrichment of phosphorylated peptides was performed 
applying the SIMAC protocol as previously described [119]. 
Unbound peptide pools (non-modified peptides) were dried 
in a vacuum centrifuge and reconstituted with 40 μL of 
5 mM ammonium bicarbonate (ABC), pH 9.8, and injected 
into an ÄKTA pure 25 system (GE Healthcare Life Sci-
ences) with a high pH stable X-Terra RP18 column (C18; 
2.1 mm × 150 mm; 3.5 μm) (Waters). Mobile phases were 
5 mM ammonium formate in 90% ACN at pH 9.8 (buffer 
B) and 5 mM ammonium formate in water at pH 9.8 (buffer 
A). Column gradient was developed in an 80-min three-step 
gradient from 5% B to 30% B in 5 min, 30% B to 60% B in 
40 min, 15 min in 60% B, and 60% B to 90% B in 20 min. 
Column was equilibrated in 95% B for 30 min and 2% B for 
10 min. Thirteen fractions were collected and evaporated 
under vacuum. Peptide fractions were reconstituted into a final 
concentration of 0.5 µg/µL of 2% ACN, 0.5% FA, 97.5% Mil-
liQ-water prior to mass spectrometric analysis. Then, peptide 
mixtures were separated by reverse phase chromatography 
Table 2  Gene symbols and 
TaqMan probes used in frontal 
cortex and subcortical white 
matter
Gene Full name Reference
ALDH1L1 Aldehyde dehydrogenase 1 family member L1 Hs01003842_m1
AQP4 Aquaporin-4 Hs00242342_m1
CNP 2′,3′-Cyclic nucleotide 3′ phosphodiesterase Hs00263981_m1
GFAP Glial fibrillary acidic protein Hs00909233_m1
GJA1 Gap junction alpha-1 protein/connexin-43 Hs00748445_s1
GUS-β β-Glucuronidase Hs00939627_m1
MAG Myelin-associated glycoprotein Hs01114387_m1
MAL Mal, T-cell differentiation protein Hs00360838_m1
MBP Myelin basic protein Hs00921945_m1
MCT1 Solute carrier family 16 (monocarboxylic acid transporters), member 1 Hs01560299_m1
MOBP Myelin-associated oligodendrocyte basic protein Hs01094434_m1
MOG Myelin oligodendrocyte glycoprotein Hs01555268_m1
MPC1 Mitochondrial pyruvate carrier 1 Hs00211484_m1
MYRF Myelin regulatory factor Hs00973739_m1
NG2 Neural/glial antigen 2 Hs00426981_m1
OLIG1 Oligodendrocyte transcription factor 1 Hs00744293_s1
OLIG2 Oligodendrocyte lineage transcription factor 2 Hs00377820_m1
PLP1 Proteolipid protein 1 Hs00166914_m1
SLC1A2 Solute carrier family 1 (glial high affinity glutamate transporter), member 2 Hs01102423_m1
SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1 Hs01102423_m1
SOX-10 SRY-Box 10 Hs00366918_m1
UCP4 Mitochondrial uncoupling protein 4 Hs00188687_m1
UCP5 Mitochondrial uncoupling protein 5 Hs00605850_m1
YKL40 Chitinase 3 like 1 Hs01072228_m1
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using an Eksigent nanoLC ultra 2D pump fitted with a 75-μm 
ID column (Eksigent 0.075 × 250). Samples were first loaded 
for desalting and concentration into a 2-cm-length 100-μm ID 
precolumn packed with the same chemistry as the separating 
column. Mobile phases were 100% water, 0.1% formic acid 
(FA) (buffer A), and 100% acetonitrile 0.1% FA (buffer B). 
Non-modified peptide fractions were analysed under the fol-
lowing conditions. Column gradient was developed in a 135-
min three-step gradient from 2% B to 30% B in 90 min, from 
30% B to 40% B in 10 min, and from 40 to 80% in 10 min. 
Column was equilibrated in 97% B for 3 min and 2% B for 
23 min. During all the process, precolumn was in line with 
column and flow maintained all along the gradient at 300 nl/
min. Eluting peptides from the column were analysed using 
a 5600 Triple-TOF system (Sciex). Data acquisition was car-
ried out using a survey scan in a mass range from 350 m/z 
to 1250 m/z for 250ms. The top 35 peaks were selected for 
fragmentation. Minimum accumulation time for MS/MS was 
set at 11 ms giving a total cycle time of 3.8 s. Product ions 
were scanned in a mass range from 100 m/z up to 1500 m/z 
and excluded for further fragmentation for 15 s. In the case of 
fractions that contained the phosphorylated peptides derived 
from FC and WM, column gradient was developed in 140-min 
two-step gradient from 2 to 35% B in 100 min and from 35 to 
70% in 20 min. Column was equilibrated in 95% B for 5 min 
and 2% B for 15 min. Precolumn was in line with column and 
flow maintained all along the gradient at 300 nl/min. Elut-
ing peptides from the column were analysed using a 5600 
Triple-TOF system (Sciex) following the same conditions as 
the non-modified peptides.
Data analysis
The raw MS/MS spectra searches were processed using the 
MaxQuant software (v.1.5.8.3) [120] and searched against 
the Uniprot proteome reference for Homo sapiens (Proteome 
ID: UP000005640_9606, February 2019). The parameters 
used were as follows: initial maximum precursor (25 ppm) 
fragment mass deviations (40 ppm); variable modification 
(methionine oxidation and N-terminal acetylation) and fixed 
modification (MMTS); enzyme (trypsin) with a maximum 
of 1 missed cleavage; minimum peptide length (7 amino 
acids); and false discovery rate (FDR) for PSM and protein 
identification (1%). Frequently observed laboratory contami-
nants were removed. Protein identification was considered 
valid with at least one unique or “razor” peptide. The protein 
quantification was calculated using at least 2 razor + unique 
peptides, and statistical significance was calculated with a 
two-way Student t test (p < 0.05). A 1.3-fold change cut-
off was used. Proteins with iTRAQ ratios below the low 
range (0.77) were considered to be down-regulated, whereas 
those above the high range (1.3) were considered to be up-
regulated. Additionally, in the analysis of the frontal cortex 
and white matter phosphorylated fractions, phosphoserine, 
phosphothreonine, and phosphotyrosine were chosen as vari-
able modifications for database searching. The Perseus soft-
ware (version 1.5.6.0) [120] was used for statistical analysis 
and data visualization. Search result files and MS raw data 
were deposited in the ProteomeXchange Consortium (https 
://prote omece ntral .prote omexc hange .org) via the PRIDE 
partner repository with the dataset identifiers PXD015768 
(Reviewer account details: Username: reviewer51422@ebi.
ac.uk; Password: vhhPC599).
The identification of significantly dysregulated regula-
tory/metabolic pathways in frontal cortex and white matter 
proteomic datasets was performed using Metascape [138]. 
The interactome of tau was analysed using FpClass (https 
://dcv.uhnre s.utoro nto.ca/FPCLA SS/) [66], a database of 
predicted protein–protein interactions (PPIs), the curated 
Biological General Repository for Interaction Datasets 
(BioGRID: https ://thebi ogrid .org) [95], and STRING [110].
Animals and tissue processing
Wild-type C57BL/6 mice from our colony were used. All 
animal procedures were carried out following the guidelines 
of the European Communities Council Directive 2010/63/
EU and with the approval of the ethical committee of the 
University of Barcelona, Spain.
Four series of mice were unilaterally inoculated with 
sarkosyl-insoluble fractions from the frontal cortex of 
GGT linked to MAPT P301T mutation (case 1): (i) mice 
aged 12 months in the right hippocampus and killed at 
18–19 months (survival 6–7 months), n = 4; (ii) mice aged 
7 months in the right corpus callosum and killed at the age 
of 11 months (survival 4 months), n = 4; (iii) mice aged 
12 months in the right corpus callosum and killed at the 
age of 18 months (survival 6 months), n = 4; and mice aged 
10 months in the right caudate/putamen (CPu) and killed 
5 months later, n = 4. Another series was inoculated in the 
right hippocampus with sarkosyl-insoluble fractions from 
the white matter of GGT case 1 at the age of 7 months and 
killed at the age of 14 months (survival 7 months), n = 4. 
Control mice included two mice inoculated in the right hip-
pocampus with sarkosyl-soluble fractions and one mouse 
inoculated with 50 mM Tris–HCl (pH 7.4) as vehicle at the 
age of 7 months and killed four months later.
For comparative purposes, WT mice aged 3–4 months 
were unilaterally inoculated in the right hippocampus or the 
corpus callosum with sarkosyl-insoluble fractions of frontal 
cortex homogenates from sGGT (mice, n = 3), and frontal cor-
tex from GGT linked to MAPT K317M mutation (mice, n = 2), 
and killed at the age of 18–19 months (survival 6–7 months).
The total number of animals, males, and females was 24.
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Inoculation into the hippocampus, lateral corpus callosum, 
and caudate/putamen
The reasons for inoculating in these particular regions were 
to assess: (a) neuronal transmission following unilateral 
injection in the hippocampus, (b) transmission along white 
matter tracts and involvement of the white matter follow-
ing unilateral inoculation in the corpus callosum, and (c) 
regional vulnerability comparing inoculation in the hip-
pocampus and the caudate/putamen.
Mice were deeply anesthetized by intra-peritoneal keta-
min/xylazine/buprenorphine cocktail injection and placed 
in a stereotaxic frame after assuring lack of reflexes. Intra-
cerebral injections were done using a Hamilton syringe; 
the coordinates for hippocampal injections were − 1.9 AP; 
−/+ 1.4 ML relative to Bregma and − 1.5 DV from the dural 
surface; the coordinates for lateral corpus callosum inocu-
lations were − 1.9 AP; −/+ 1.4 ML relative to Bregma and 
− 1.0 DV from the dural surface; the coordinates for caudate/
putamen (CPu) were 0.14 AP; − /+ 2 relative to Bregma and 
− 2.5 from the dural surface [96]. A volume of 1.5 µL was 
injected at a rate of 0.05 µL/min in the hippocampus and 
CPu, and 1.2 µL was injected at a rate of 0.1 µL/min in 
the corpus callosum. The syringe was retired slowly over a 
period of 10 min to avoid leakage of the inoculum. Follow-
ing surgery, the animals were kept in a warm blanket and 
monitored until they recovered from the anaesthesia. Car-
profen analgesia was administered immediately after surgery 
and once a day during the following two days. Animals were 
housed individually with full access to food and water.
Tissue processing
Animals were killed under anaesthesia, and the brains 
were rapidly fixed with 4% paraformaldehyde in phosphate 
buffer and embedded in paraffin. Consecutive serial coro-
nal sections 4 μm thick of the whole brain were obtained 
with a sliding microtome. De-waxed sections were stained 
with haematoxylin and eosin, stained with Gallyas silver 
method, or processed for immunohistochemistry using the 
antibodies AT8, anti-4Rtau, anti-3Rtau, MC-1, Tau-C3, 
oligomeric tau-22, PLP1 and SMI31, in addition to GFAP 
for reactive astrocytes and Iba1 for microglia. Following 
incubation with the primary antibody, the sections were 
incubated with EnVision + system peroxidase for 30 min 
at room temperature. The peroxidase reaction was visu-
alized with diaminobenzidine and  H2O2. Control of the 
immunostaining included omission of the primary anti-
body; no signal was obtained following incubation with 
only the secondary antibody. The specificity of 3Rtau and 
4Rtau antibodies in mice was tested in coronal sections 
of the brain, cerebellum, and brainstem of P301S trans-
genic mice aged 8–9 months [84]. Tau-immunoreactive 
inclusions in mice expressing mutant human 4Rtau were 
positive with anti-4Rtau antibodies but negative with anti-
3Rtau antibodies.
Double-labelling immunofluorescence was carried out 
on de-waxed sections, 4 μm thick, which were stained 
with a saturated solution of Sudan black B (Merck, DE) 
for 15 min to block autofluorescence of lipofuscin gran-
ules present in cell bodies, and then rinsed in 70% ethanol 
and washed in distilled water. The sections were boiled 
in citrate buffer to enhance antigenicity and blocked for 
30 min at room temperature with 10% foetal bovine serum 
diluted in PBS. Then, the sections were incubated at 4 °C 
overnight with combinations of AT8 and one of the fol-
lowing primary antibodies: GFAP, Iba1, Olig2, phospho-
rylated p38 at Thr180-Tyr182 (p38-P Thr180-Tyr182), 
and anti-histone H4 (acetyl K12). Other sections were 
immunostained with anti-phospho-tauThr181, anti-NeuN, 
and anti-histone H3 (di-methyl K9) (see Table 1 for the 
characteristics of the antibodies). After washing, the sec-
tions were incubated with Alexa488 or Alexa546 fluores-
cence secondary antibodies against the corresponding host 
species. Nuclei were stained with DRAQ5™. Then, the 
sections were mounted in Immuno-Fluore™ mounting 
Fig. 1  Representative neuropathological alterations in GGT linked 
to MAPT P301T mutation, case 1. Phospho-tau deposition identified 
with the antibody AT8 is seen in neurons and glial cells in the CA1 
region of the hippocampus (CA1), dentate gyrus (DG), entorhinal 
cortex (EC), frontal cortex (FC), locus ceruleus (LC), and anterior 
horn of the spinal cord (SC) (a–f), among other regions. Tau depos-
its are not stained with anti-3Rtau antibodies (temporal cortex: TC) 
(g), but they are strongly immunoreactive with anti-4Rtau antibod-
ies in all the assessed regions (here represented by the putamen: Put, 
temporal cortex: TC, and occipital cortex: OccC, frontal cortex, cor-
pus callosum, internal capsule, and white matter of the frontal lobe) 
(h–n). At higher magnification, globular astrocytic inclusions (GAIs) 
are characterized by several oval-shaped or round peripheral phos-
pho-tau-immunoreactive deposits in the proximal region of the astro-
cyte branches (k). Oligodendrocytes in the corpus callosum (Corp 
call), internal capsule (Int cap), and frontal subcortical white matter 
(FWM) have globular inclusions (GOIs), but some oligodendroglial 
inclusions are identical to coiled bodies (i–n). Phospho-tau immu-
noreactivity is also abundant in the neuropil of the grey matter and 
white matter. GAIs and GOIs are also stained with anti-PtauThr181 
antibodies (o), and with MC1 antibodies which recognize abnormal 
tau conformation (as seen in the FC and Put) (p, q). Tau deposits in 
neurons and glial cells, including those in the hippocampus (CA1 
region and dentate gyrus (DG), temporal cortex (TC), amygdala 
(Amyg), and nuclei of the brain stem such as the substantia nigra 
(SN) contain tau oligomers as revealed with the antibody tau-22 (r–
v). Tau deposits, particularly in GAIs and GOIs, are also stained with 
Tau-C3, which recognizes tau truncated at Asp421, in most regions 
including the cerebral cortex (FC and TC) and white matter (WM) 
(x, y1, y2, y3). GAIs are labelled with thick black arrows, GOIs with 
thick white arrows and coiled bodies with thin arrows. Some neurons 
and glial cells are stained with anti-ubiquitin antibodies (z). Paraffin 
sections processed for immunohistochemistry slightly counterstained 
with haematoxylin; a–j, p–e, h–j, s–v, z, bar = 45 μm; k–o, p–r, w–
y3, bar = 50 μm
▸
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medium, sealed, and dried overnight. Sections were exam-
ined with a Leica TCS-SL confocal microscope. Quantita-
tive studies were carried in the ipsilateral corpus callosum 
in three non-consecutive sections per case using double-
labelling immunofluorescence and confocal microscopy. 
Data were expressed as the percentage of oligodendrocytes 
(as revealed with the Olig2 antibody) with tau deposits 
(as seen with the antibody AT8) compared with the total 
number of oligodendrocytes in the same field following 
the same protocol as used in human brains.
In situ end-labelling of nuclear DNA fragmentation 
 (ApoptTag® peroxidase in situ apoptosis detection kit, 
Merck) was used to visualize apoptotic cells. The brains 
of newborn irradiated rats (2Gys) with a survival time of 
24 h were fixed in 4% paraformaldehyde and embedded in 
paraffin; de-waxed sections were processed in parallel with 
tissue samples from inoculated mice and used as positive 
controls of apoptosis.
Fig. 1  (continued)
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Results
Neuropathological characteristics of GGT linked 
to MAPT P301T mutation
Frontal atrophy was found in every case, accompanied by 
parietal atrophy in cases of the second pedigree. The tempo-
ral cortex and hippocampus were atrophic in case 1. Micro-
scopic examination revealed common alterations but with 
variable distribution and intensity. Neuron loss, spongiosis 
in the upper cortical layers, occasional ballooned neurons, 
marked astrocytic gliosis (revealed with anti-GFAP antibod-
ies), and mild microgliosis (revealed with Iba1 antibody) 
were severe in the cerebral cortex; neuron loss also occurred 
in diencephalic nuclei and nuclei of the basal forebrain, and 
in the substantia nigra and locus ceruleus with neuromela-
nin granules in the neuropil. αB-crystallin immunoreactivity 
was seen in ballooned neurons and in a subpopulation of 
reactive astrocytes. Myelin pallor, as seen with Klüver–Bar-
rera staining, and PLP1, MBP and CNPase immunohisto-
chemistry, together with loss of neurofilaments (as seen with 
RT97 immunohistochemistry), was found in the white mat-
ter, corpus callosum, internal capsule, and pyramidal tracts. 
Sudan black identified occasional perivascular macrophages 
around blood vessels and small granules in the lobar white 
matter, internal capsule, and corpus callosum.
Phospho-tau deposits in neurons, astrocytes, oligoden-
drocytes, and threads were present in every case, although 
with variable distribution and morphology from one case 
to another. Most dramatic deposits occurred in case 1.
Neurons with phospho-tau deposits were localized in 
the prefrontal cortex, motor cortex, primary sensory cor-
tex, parietal cortex, temporal cortex, insula, occipital cor-
tex, hippocampus (including CA1, CA2, CA3 regions and 
hilus), dentate gyrus, subiculum, entorhinal cortex, Meynert 
nucleus, caudate, putamen, pallidum, thalamus, substantia 
nigra, midbrain tectum, locus ceruleus, pontine nuclei, pon-
tine tectum, and anterior horn of the spinal cord.
Globular astrocytic inclusions (GAIs) were very abun-
dant in the same regions as described for phospho-tau 
deposits in neurons in case 1. GAIs were more rarely seen 
in the anterior horn of the spinal cord. GAIs were much 
lower in numbers in the cerebral cortex and absent in the 
other brain regions in cases 2, 3, and 4.
Globular oligodendroglial inclusions (GOIs) and coiled 
bodies were abundant in most grey matter regions, and in 
the subcortical white matter, corpus callosum, internal cap-
sule, and fascicles of the basal forebrain in case 1. GOIs and 
coiled bodies were less common or absent in the white mat-
ter and other brain regions in the three cases of pedigree 2.
Phospho-tau-immunoreactive threads in the cerebral 
cortex and white matter paralleled the distribution and 
intensity of grey and white lesions in every individual 
case; most severe lesions were seen in case 1 when com-
pared with cases of pedigree 2.
Neurons, glial inclusions, and threads were stained with 
antibodies AT8, anti-P-tauThr181, anti-P-tauSer422, 4Rtau, 
and MC-1. Inclusions were Tau-C3 positive in a subpopula-
tion of glial cells and neurons in two cases (case 1 and case 
2) but rarely positive in the other two (cases 3 and 4). Inclu-
sions in case 1 were particularly positive with the antibody 
tau-22 which recognizes oligomeric tau. Inclusions were 
negative with anti-3Rtau antibodies. Many oligodendroglial 
inclusions were positive with anti-ubiquitin and anti-p62 
antibodies. The images in Fig. 1 illustrate neuropathologi-
cal characteristics in case 1. Neuropathological findings in 
case 3 are shown in Supplementary Fig. 1.
In addition to the individual variations in the distribution 
and magnitude of lesions, differential morphological details 
were also noted among cases. Neuronal phospho-tau depos-
its in case 1 were granular, perinuclear halos, dense deposits 
occupying all the cytoplasm, and tangles. Neuronal depos-
its in cases 2, 3 and 4 were granular, globular tangles, and 
round inclusions mimicking Pick bodies. Neuronal skein-
like, and globular and dense inclusions in motor nuclei of 
the brain stem and spinal cord were observed mainly in case 
1, but seldom encountered in case 3. Regarding astroglial 
deposits, GAIs in case 1 were perikaryal globular structures 
and coarse tufted-like deposits, sometimes forming rough 
dense perinuclear horse-shaped structures. In addition, astro-
cytes with longer radiating processes and structures similar 
to astrocytic plaques were also observed in case 1. GAIs 
with long processes rather than forming perikaryal struc-
tures were found in cases 2, 3, and 4 (Fig. 2). Many GAIs 
did not show mature morphology but variable numbers of 
perinuclear phospho-tau-positive deposits and short radiat-
ing fusiform or globular processes which were interpreted 
as immature forms [116].
Double-labelling immunofluorescence and confocal 
microscopy of the frontal cortex and white matter in case 
1 using antibodies tau-C3, which recognizes tau truncated 
at aspartic acid 421, and anti-phospho-specific tau Thr181, 
showed that about 70% of phosphorylated tau-immunore-
active inclusions in astrocytes corresponding to GAIs, and 
oligodendrocytes corresponding to GOIs and coiled bod-
ies, were immunostained with anti-Tau-C3 antibodies (data 
not shown). These numbers were similar to those already 
reported in sporadic GGT [40]. Similarly, about 70% of 
phospho-tau-immunoreactive inclusions in neurons, astro-
cytes, and oligodendrocytes, as revealed with AT8, were 
stained with tau-22 antibody.
Gallyas staining showed variable positivity in neu-
rons, varying from tangle-like inclusions, dense diffuse 
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staining, fine granular staining, and faint diffuse staining 
to more common Gallyas-negative tau-positive neurons (as 
revealed in consecutive sections immunostained with AT8 
antibodies). GAIs were negative, although faint granular 
Gallyas-positive deposits were very rarely seen in the dis-
tal region of astrocytic processes or in the cytoplasm of a 
few astrocytes. In contrast, coiled bodies and GOIs were 
regularly positive in the four cases (Supplementary Fig. 5).
β-Amyloid and α-synuclein deposits were absent. TDP-
43 immunohistochemistry did not disclose abnormal local-
ization and distribution of this protein. Small blood vessel 
disease accompanied by mild status cribosus in basal gan-
glia was the only additional age-related lesion.
mRNA expression of selected genes in frontal cortex 
and adjacent subcortical white matter in GGT linked 
to MAPT P301T mutation
Selected genes expressed in astrocytes and oligodendrocytes 
were assessed with RT-qPCR. In frontal cortex, GFAP, 
ALDH1L1, YKL40, and GJA1 were significantly increased in 
GGT linked to MAPT P301T mutation when compared with 
controls (p = 0.0013, p = 0.000, p = 0.004, and p = 0.000, 
respectively). MPC1 was significantly decreased (p = 0.006). 
AQP4, SLC1A2, UCP4, and UCP5 mRNA expression did 
not differ in GGT when compared with controls. In contrast 
to astrocytes, oligodendrocyte- and myelin-related genes 
were not significantly altered in frontal cortex in GGT 
cases when compared with controls, with the exception of 
NG2, which was significantly increased in GGT (p = 0.02). 
However, a trend to reduced expression was noted after the 
examination of dot graphs (Supplementary Fig. 2).
In contrast to frontal cortex, the expression of astro-
cyte-related genes was preserved in the subcortical white 
matter in GGT cases when compared with controls, with 
the exception of a significant decrease in the expression 
of MPC1 (p = 0.006). However, the expression of OLIG1 
and OLIG2 was significantly reduced in the white matter in 
GGT (p = 0.004 and 0.02, respectively). In line with these 
findings, the mRNA expression of myelin-related genes 
MBP, PLP1, CNP, MAG, MAL, MOG, and MOBP was 
significantly decreased in GGT when compared with con-
trols (p = 0.003, p = 0.001, p = 0.001, p = 0.008, p = 0.000, 
p = 0.004, and p = 0.009, respectively). Finally, mRNA 
expression of SLC2A1 and MCT1 was significantly reduced 
in GGT when compared with control cases (p = 0.04 and 
p = 0.015, respectively) (see Supplementary Fig. 3 for dot 
graphics).
Expression of proteins related to astrocytes 
and oligodendrocytes in GGT linked to MAPT P301T 
mutation
Astrocytic gliosis was accompanied by increased expres-
sion of YKL40 not only in the number of positive cells but 
also in the density of the reaction in a subpopulation of 
astrocytes in GGT (Fig. 3a, b). Aquaporin AQ4, encoded 
by AQP4, was expressed in astrocyte processes includ-
ing podocytes around blood vessels in normal conditions; 
however, AQ4 immunoreactivity was much denser, giving 
rise to a jammed meshwork in GGT (Fig. 3c, d). Gluta-
mate transporter GLT1 (excitatory amino acid transporter 
2: EAAT2), encoded by SLC1A2, was also localized in 
the branches of astrocytes, forming a delicate net in grey 
matter of control brains; this pattern was markedly altered 
in affected areas of the cerebral cortex in GGT in which 
only scattered astrocytes presented GLT1 immunoreactiv-
ity (Fig. 3e–h). Solute carrier family 2 member 1: glucose 
transporter GLUC-t (here named in this way and not as 
GLT1 to avoid confusion with the glutamate transporter) 
encoded by SLC2A1, was mainly expressed in the vessel 
wall of capillaries but also as a diffuse component of the 
neuropil in control brains. GLUC-t expression was abnor-
mal in the cerebral cortex and white matter in GGT cases 
(particularly in case 1) due to the increased number of 
capillaries and reduced immunoreactivity in the neuropil 
(Fig. 3i, j). Quantification of capillaries in the frontal cor-
tex revealed a significant increase when compared with 
controls (control: 10.92 ± 0.28 vs. 47.7 ± 1.44; p = 0.000). 
Increased number of capillaries can be interpreted as the 
result of cortical atrophy, but the presence of focal cap-
illary sprouting and foci of disrupted capillaries in grey 
matter and white matter points to a possible primary dis-
order of capillaries in GGT (Fig. 3k, l).
Mitochondrial pyruvate carrier 1, encoded by MPC1, was 
expressed mainly in neurons in the cerebral cortex and in a 
subpopulation of glial cells in the grey and, particularly, the 
white matter, where it was identified as small confluent cyto-
plasmic granules. MPC1 immunoreactivity was markedly 
reduced in individual neurons in the cerebral cortex in GGT 
when compared with controls, but MPC1 immunoreactivity 
Fig. 2  Characteristics of neuronal and astroglial phospho-tau depos-
its in the frontal cortex in GGT linked to MAPT P301T mutation; 
a–i: case 1; j–o: cases 3 and 4. In case 1, phospho-tau deposits, as 
revealed with the AT8 antibody, are finely granular in the cytoplasm, 
or form perinuclear halos, or globular tangles (long white arrow) (a, 
b, d, g). In cases 3 and 4, phospho-tau deposits are granular (long 
white arrow), globular, or round Pick-like bodies (short white arrow) 
(j, k). Astrocytic deposits in case 1 are typical GAIs with perikaryal 
globular structures or forming dense perinuclear inclusions of vari-
able size consistent with immature stages (short black arrow) (d–f); 
together with astrocytes with longer cell and fine processes (long 
black arrow) (h), and astrocytic plaque-like structures (asterisk) (i). 
Astrocytic deposits in cases 3 and 4 show a predominance in astro-
cytes with longer cell processes (white arrows) (l, m, o) in addition 
to typical GAIs (short black arrows). Paraffin sections processed for 
AT8 immunohistochemistry and slightly counterstained with haema-
toxylin; bar = 25 μm
◂
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was markedly increased in glial cells resembling astrocytes 
because of the distribution of their branches in the white 
matter of the same cases (Fig. 4a–d).
NG2 immunoreactivity was recognized as small granules 
in the cytoplasm of a subpopulation of glial cells, mainly 
satellite cells, in the cerebral cortex, and in a number of glial 
cells in the white matter in control brains. The number of 
glial cells positive with the NG2 antibody was greater in the 
cerebral cortex and white matter in GGT cases when com-
pared with controls (Fig. 4e–h). CNPase, used as a marker of 
myelin, was expressed in the white matter and intra-cortical 
myelin fibres; the number of CNPase-immunoreactive fibres 
was markedly reduced in the white matter in GGT cases, and 
this loss was accompanied by disruption of the remaining 
fibres (Fig. 4i–k). Similar results were obtained with anti-
PLP1 and anti-MBP antibodies (data not shown). Finally, in 
order to reveal axonal damage, SMI31 immunohistochemis-
try revealed dramatic axonal disruption, axonal varicosities, 
and axonal spheroids along nerve fibres in the white matter 
(Fig. 4m–r).
To analyse whether altered protein expression of differ-
ent proteins was linked to phospho-tau deposition within 
the same cells, selected proteins were assessed with double-
labelling immunofluorescence and confocal microscopy. 
Ballooned neurons, many reactive astrocytes, and scattered 
oligodendrocytes contained αB-crystallin (Fig. 4l), but dou-
ble-labelling immunofluorescence disclosed no co-localiza-
tion of phospho-tau (antibody P-tauThr181) or αB-crystallin 
in the vast majority of neurons and astrocytes containing one 
of these proteins (data not shown), in agreement with previ-
ous data detailed elsewhere [85]. A similar situation occured 
in relation to YKL40 since it is mainly expressed in reactive 
astrocytes independently of the presence of protein aggre-
gates (data not shown), as observed in many other neurode-
generative diseases [33]. In contrast, phospho-tau deposition 
in astrocytes dramatically modified the distribution of the 
cytoskeletal protein GFAP in GGT as revealed by double-
labelling immunohistochemistry and confocal microscopy 
(data not shown) in agreement with previous observations 
in sporadic GGT and other tauopathies [33, 34].
Fig. 3  YKL40 is lightly expressed in very small subpopulations of 
astrocytes in the cerebral cortex in controls (Contr), but the num-
ber of YKL40-positive astrocytes, and the intensity of the immu-
noreactions per cell, are largely increased in cortical astrocytes in 
GGT linked to MAPT P301T mutation (a, b). AQ4 is also markedly 
increased in the cerebral cortex in GGT compared with controls (c, 
d). In contrast, the expression of the glutamate transporter GLT1 is 
reduced in the different regions of the cerebral cortex in GGT when 
compared with controls (e–h). The glucose transporter CLUC-t is 
expressed in the vessel wall of capillaries, and diffusely so in the neu-
ropil in the cerebral cortex in control brains. The number of GLUC-t-
immunoreactive capillaries is largely increased in the cerebral cortex 
in GGT linked to MAPT P301T mutation. This is accompanied by 
focal sprouting of capillaries in the cerebral cortex (thin arrow) and 
focal disruption of capillaries (thick arrow) in the frontal cortex and 
white matter in GGT (i–l). FC frontal cortex, TC temporal cortex, 
WM white matter. Case 1; paraffin sections processed for immuno-
histochemistry slightly counterstained with haematoxylin; a–h, k–l, 
bar = 45 μm; i, j bar = 100 μm
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In order to learn about the impact of phospho-tau dep-
osition in astrocytes containing hyper-phosphorylated 
tau deposits, double-labelling immunofluorescence to 
mitochondrial pyruvate carrier 1 (MPC1) and confocal 
microscopy disclosed similar MPC1 immunoreactivity in 
phospho-tau-containing glial cells and in glial cells with-
out phospho-tau deposits in the frontal cortex of GGT 
cases (Fig. 5a). Similarly, the expression of mitochondrial 
uncoupling protein 4 (UCP4) was similar in glial cells 
with and without phospho-tau deposits. Robust UCP4 
immunoreactivity was also observed in neurons containing 
phospho-tau deposits (Fig. 5b). In contrast, mitochon-
drial uncoupling protein 5 (UCP5) immunoreactivity was 
almost absent in GAIs when compared with neighbouring 
glial cells without phospho-tau deposits (Fig. 5c).
Double-labelling immunofluorescence and confocal 
microscopy to H3K9me2 and H4K12ac, and phospho-tau 
antibodies (P-tauThr181 and AT8, respectively), showed 
similar histone H4K12ac and H3K12ac immunoreactiv-
ity in the nuclei of cells with and without phospho-tau 
depositions (Fig. 5d–g).
Fig. 4  GGT linked to MAPT P301T mutation. Mitochondrial pyru-
vate carrier 1 (MPC1) is expressed in neurons in the cerebral cortex 
and in a subpopulation of glial cells in the frontal cortex (FC) and 
white matter (WM) in control (Contr) and GGT cases. MPC1 immu-
noreactivity is markedly reduced in neurons (decreased numbers of 
intracytoplasmic granules), but dramatically augmented in glial cells 
resembling astrocytes in the white matter in GGT when compared 
with controls (a–d). NG2 immunoreactivity is found in a subset 
of glial cells, mainly satellite cells, in the cerebral cortex, and in a 
number of glial cells in the white matter. The number of glial cells 
with NG2-immunoreactive granules is higher in the cerebral cortex 
and white matter in GGT cases when compared with controls (e–h). 
CNPase, used as a marker of myelin, is markedly decreased in the 
white matter in GGT when compared with controls, with disrup-
tion of remaining fibres in the white matter seen in GGT cases (i–k). 
αB-crystallin immunoreactivity decorates ballooned neurons and a 
subpopulation of astrocytes and oligodendrocytes in GGT (l). SMI31 
immunohistochemistry reveals reduced numbers of nerve fibres, vari-
cosities, and axonal ballooning, and SMI31-immunoreactive inclu-
sions in the white matter in GGT cases (n–r) when compared with 
the white matter in controls (m). Case 1; paraffin sections processed 
for immunohistochemistry slightly counterstained with haematoxylin; 
a–h, k, bar = 45 μm; i, j–l, m–r, bar = 100 μm
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Finally, double-labelling immunofluorescence and 
confocal microscopy to phosphorylated kinase p38 
(p38-P Thr180-Tyr182) and AT8 disclosed p38-P 
immunoreactivity restricted to neurons and glial cells 
containing phospho-tau deposits in about 70% of the 
population bearing tau deposits (Fig. 5h).
Fig. 5  Frontal cortex in GGT 
linked to MAPT P301T muta-
tion (case 1). Double-labelling 
immunofluorescence and 
confocal microcopy of the 
frontal cortex (FC) in case 1 
using antibodies anti-MPC1 (a), 
UCP4 (b), or UCP5 (c) (green), 
and anti-P-tau Thr181 or AT8 
(red). MPC1 is expressed 
equally in astrocytes with tau 
deposits (thin arrows) and with-
out tau deposits (thick arrow) 
(a). Similarly, UCP4 is found in 
astrocytes bearing phosphoryl-
ated tau (thin arrows) and in 
cells without tau deposits (thick 
arrows) (b). In contrast, UCP5 
is absent in GAIs deposits 
(thin arrows) when compared 
with cells without tau deposits 
(thick arrows) (c). Nuclei are 
counterstained with DRAQ5™ 
(blue). Paraffin sections, a–c, 
bar = 30 μm. d–g Expression of 
histones in frontal cortex and 
white matter in GGT (case 1). 
H3K9me2 immunoreactivity is 
expressed equally in cells with 
(thin arrows) and without (thick 
arrows) phosphorylated tau 
deposits (P-tauThr181 antibody) 
(d, e). Similarly, H4K12ac 
immunoreactivity is expressed 
equally in oligodendrocytes 
with coiled bodies (f) and 
globular inclusions (g) (AT8 
antibody) (thin arrows), and in 
oligodendroglia cells without 
tau inclusions (thick arrows). 
Nuclei are counterstained with 
DRAQ5™ (blue). Paraffin 
sections, d bar = 20 μm; e–g 
bar = 30 μm. h phosphorylated 
p38 Thr180-Tyr182 (p38P) 
co-localizes with AT8-immu-
noreactive deposits (asterisk) in 
frontal cortex in GGT. Paraffin 
section without nuclear counter-
staining, bar = 10 μm
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Neuroanatomical proteostatic imbalance in GGT 
linked to MAPT P301T mutation
With the aim of gaining insight into the proteostatic dear-
rangement present in GGT, mass-spectrometry-based quan-
titative proteomics was applied at the level of frontal cortex 
and subcortical white matter. Proteome monitoring revealed 
78 and 19 differentially expressed proteins in frontal cortex 
and white matter, respectively, in GGT cases with respect 
to controls (Supplementary Tables 1 and 2 and Fig. 6a, 
b), uncovering 4 common differentially underexpressed 
proteins in both areas (neurofilament light, neurofilament 
heavy, internexin neuronal intermediate filament protein α, 
and complexin 1: NEFL, NEFH, INA and CPLX1, respec-
tively). Moreover, phosphoproteome profiling revealed 
101 and 23 differential phosphopeptides (mapping to 74 
and 15 proteins) corresponding to frontal cortex and white 
matter, respectively. Changes in the phosphorylation state 
Fig. 6  Frontal cortex (FC) and 
white matter (WM) proteomic 
disturbances in GGT linked 
to MAPT P301T mutations 
compared with controls. Heat 
map represents the differentially 
expressed proteins between 
GGT cases and controls in 
WM (a) and FC (b); red and 
green, up-regulated and down-
regulated proteins, respectively. 
c Number of proteome and 
phosphoproteome alterations 
in both areas. d Specific-cell-
type enrichment of proteostatic 
alterations detected in FC and 
subcortical WM
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observed in 8 cortical proteins (aquaporin 4, glial fibrillary 
acidic protein, heat shock protein family B (small) member 
1, heat shock protein family B (small) member 6, neurofila-
ment light, neurofilament heavy, neurofilament medium, and 
solute carrier family 4 member 10: AQ4, GFAP, HSPB1, 
HSPB6, NEFH, NEFL, NEFM, SLC4A10, respectively), 
and in one white matter protein (NEFH), may be associated 
with total protein variations. Three cytoskeletal-associated 
phosphoproteins were commonly deregulated in both struc-
tures: microtubule-associated protein tau, microtubule-
associated protein A, and microtubule-associated protein 
B (MAPT, MAP1A, and MAP1B, respectively) (Supple-
mentary Tables 1 and 2). To characterize the metabolic 
modulation in frontal and subcortical white matter, differ-
ential proteomic and phosphoproteomic maps (Fig. 6c) were 
merged and functionally analysed. A cell-type enrichment 
analysis across frontal cortex and white matter differential 
datasets was performed using cell-type protein marker lists 
derived from four purified brain cell types: neuron, astro-
cyte, microglia, and oligodendrocyte [105, 137]. As shown 
in Fig. 6d, part of the frontal cortex alterations corresponded 
to oligodendrocytes (12%), astrocytes (10.5%), and neurons 
(5%) (Supplementary Table 3). In the case of white matter, 
18% of proteostatic alterations were specific to oligoden-
drocytes, and 3% of astrocytic and neuronal nature (Fig. 6d, 
Supplementary Table 3). All these data shed new light on 
the molecular disturbances that accompany tau deposition 
across each cellular homeostasis in GGT. To amass a more 
detailed description of the molecular mechanisms involved 
in frontal cortex and white matter in GGT, subsequent anal-
yses were performed to explore the differential (phospho)
proteome distributions across specific pathways/biofunc-
tions. Axon guidance, exocytosis, chaperone-mediated pro-
tein folding, and myelination were part of the significantly 
over-represented dysregulated processes in the frontal cortex 
(Fig. 6, Supplementary Table 4). Interestingly, our data point 
up a common deregulation of specific protein clusters related 
to microtubule polymerization and synaptic transmission 
(Fig. 7, Supplementary Table 4). A deep synaptic ontology 
analysis (Table 3, Supplementary Table 5) revealed that pro-
tein derangements occur at the presynaptic and postsynaptic 
levels, being partially involved in the structural integrity of 
the synapse in GGT cases linked to MAPT P301T mutation.
Other GGT cases
Sporadic GGT 
The neuropathological study of the sGGT case revealed 
severe frontotemporal atrophy with marked enlargement of 
the lateral ventricles and atrophy of the perisylvian region, 
reduced white matter, marked atrophy of the corpus cal-
losum, and moderate atrophy of the caudate and putamen, 
as well as the thalamus. The microscopical study revealed 
marked neuron loss and astrocytic gliosis in the cerebral 
cortex. Phospho-tau-immunoreactive neurons were seen 
in the cerebral cortex (particularly in the frontal cortex), 
hippocampus, diencephalon, substantia nigra, reticular 
formation, and motor nuclei of the brainstem. In addition 
to neurons, accumulation of phospho-tau was present in 
astrocytes forming GAIs (which were less abundant in the 
frontal cortex when compared with the other GGT cases 
assessed in this series), in oligodendrocytes forming GOIs 
(very abundant in the frontal white matter) and, less com-
monly, coiled bodies. Phospho-tau deposits in neurons had 
variegated morphologies including small granular depos-
its, round or oval-shaped cytoplasmic inclusions, coarse 
granular cytoplasmic deposits, dense inclusions occupying 
all the cytoplasm, and skein-like inclusions in motor nuclei 
of the brainstem; tangles were not observed. Similar skein-
like deposits were found in the motor neurons of the spinal 
cord. Phospho-tau deposits in astrocytes were scarce and 
reminiscent of small GAIs. In contrast, GOIs were often 
large, globose, and often bilobulated, but coiled bodies were 
very rare in the white matter (see case 1, [38]). Phospho-tau 
inclusions were positive with antibodies against 4Rtau but 
negative with antibodies against 3Rtau excepting a minor-
ity of glial deposits. Tau deposits in neurons, astrocytes, 
and oligodendrocytes were stained with antibodies against 
P-tauThr181, P-tauSer422, AT8, and MC-1; a subpopulation 
of oligodendroglial inclusions was stained with anti-Tau-C3 
and anti-ubiquitin antibodies, but neurons were only very 
rarely so, as detailed elsewhere [40]. GOIs were also stained 
with antibodies against oligomeric tau (data not shown). 
GAIs were Gallyas-negative and GOIs Gallyas-positive 
(Supplementary Fig. 5).
Familial GGT linked to MAPT K317M mutation
The neuropathological study of GGT linked to MAPT 
K317M mutation [40, 135] showed marked atrophy of 
the frontal and temporal lobes, and depigmentation of 
the substantia nigra. On microscopical examination, the 
present information complements and offers additional 
details to the original report [135]. Severe neuron loss 
and spongiosis was found in the frontal and temporal cor-
tices, primary motor cortex, substantia nigra, and motor 
nuclei of the medulla oblongata. The corticospinal tracts 
showed severe demyelination at the level of the bulbar 
pyramidal tracts. The spinal cord was not available for 
study in this case, but neuropathological examination of 
the spinal cord of the subject’s affected brother showed 
severe demyelination and axonal loss in the pyramidal 
tracts and loss of motor neurons in the anterior horn of 
the spinal cord [135]. Astrocytic gliosis, as revealed with 
GFAP immunohistochemistry, was marked in all these 
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regions. YKL40-immunoreactive astrocytes were numer-
ous, and they were of huge size and with robust cellular 
processes in the cerebral cortex. Tau immunohistochem-
istry revealed massive deposition of phospho-tau in neu-
rons, astrocytes, and oligodendrocytes in all the above-
mentioned regions and in the hippocampus, entorhinal 
cortex, thalamus, striatum, subthalamus, hypothalamus, 
mammillary bodies, and nuclei of the brainstem. Phospho-
tau deposits in neurons were variable in morphology and 
manifested as small diffuse granular cytoplasmic deposits, 
large aggregates, and globular tangles. Phospho-tau depos-
its in neurons of the motor nucleus of the vagus nerve 
showed skein-like and globular inclusions. Phospho-tau 
deposits in the spinal cord of the brother showed various 
Fig. 7  Enriched ontology clusters across frontal cortex (FC) and 
white matter (WM) differential (phospho)proteomes in GGT linked 
to MAPT P301T mutation. This analysis was made using Metascape. 
After the identification of all statistically enriched terms (GO/KEGG 
terms, canonical pathways, hall mark gene sets), cumulative hyper-
geometric p values and enrichment factors were calculated and used 
for filtering. Remaining significant terms were then hierarchically 
clustered into a tree based on Kappa-statistical similarities among 
their gene memberships. Then, 0.3 kappa score was applied as the 
threshold to cast the tree into term clusters. The term with the best p 
value within each cluster was selected as its representative term and 
displayed in a dendrogram. The heat map cells are coloured by their p 
values; white cells indicate the lack of enrichment for that term in the 
corresponding gene list
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types of neuronal deposits including granular deposits, 
filamentous and skein-like inclusions, globular bodies, 
and, rarely, globose tangles. Phospho-tau deposits in astro-
cytes had heterogenous morphology including abundant 
GAIs with perikaryal globular structures, rare tufted-like 
astrocytes, rare astrocytic plaques, astrocytes with radiat-
ing processes, and astrocytes with mixed morphologies. 
Phospho-tau deposits in oligodendrocytes were GOIs and 
coiled bodies. GOIs were abundant in the white matter and 
had marked polymorphism, often presenting coarse globu-
lar processes in addition to large, bizarre coiled bodies. 
All the inclusions were stained with 4Rtau antibodies but 
not with antibodies against 3Rtau, with the exception of a 
very few oligodendroglial inclusions (Fig. 8). Tau deposits 
in neurons and glial cells were stained with antibodies 
against P-tauThr181, P-tauSer422, AT8, and MC-1 and, 
less commonly, with Tau-C3, as detailed elsewhere [40], 
Table 3  Synaptic ontologies 
across frontal cortex and white 
matter differential (phospho)
proteomes
The protein count column shows the number of proteins that are annotated in SynGO [65] against each 
term. The “brain expressed” background set was selected, containing 18,035 unique genes in total of which 
1104 overlap with SynGO annotated genes. For each ontology term, a one-sided Fisher exact test was per-
formed to compare differential datasets and the “brain expressed” background set. The result is shown in 
the “p value” column. To find enriched terms within the entire SynGO ontology, a multiple testing correc-
tion using false discovery rate (FDR) was applied (q value column)
Proteins p value q value
Subcortical white matter: synaptic ontologies
 Postsynaptic intermediate filament cytoskeleton 4 3.64e−10 1.09e−9
 Postsynapse 7 1.02e−4 1.52e−4
 Presynapse 4 0.0122 0.0122
 Structural constituent of postsynaptic intermediate filament cytoskeleton 3 6.07e−8 2.43e−7
 Postsynaptic modulation of chemical synaptic transmission 4 1.52e−7 3.03e−7
 Process in the synapse 7 5.95e−4 7.93e−4
 Synapse organization 4 1.96e−3 1.96e−3
Frontal cortex: synaptic ontologies
 Postsynapse 23 5.18e−10 3.63e−9
 Postsynaptic cytoskeleton 7 1.74e−9 8.12e−9
 Presynapse 20 2.45e−9 8.57e−9
 Postsynaptic intermediate filament cytoskeleton 4 1.30e−7 3.63e−7
 Postsynaptic density, intracellular component 4 3.35e−4 7.81e−4
 Presynaptic cytosol 3 1.69e−3 3.38e−3
 Presynaptic active zone 4 5.93e−3 0.0104
 Synaptic vesicle 4 0.0125 0.0159
 Postsynaptic specialization 7 0.0113 0.0159
 Postsynaptic membrane 4 0.0121 0.0159
 Postsynaptic density 6 0.0145 0.0169
 Synaptic vesicle membrane 3 0.0300 0.0323
 Structural constituent of synapse 8 9.76e−10 7.32e−9
 Structural constituent of postsynapse 7 2.95e−9 1.48e−8
 Chemical synaptic transmission 11 3.27e−8 1.23e−7
 Synapse organization 14 1.00e−7 3.01e−7
 Synaptic vesicle cycle 10 1.81e−6 4.37e−6
 Postsynaptic modulation of chemical synaptic transmission 5 2.04e−6 4.37e−6
 Process in the presynapse 11 4.99e−6 8.32e−6
 Structural constituent of postsynaptic intermediate filament cytoskeleton 3 4.81e−6 8.32e−6
 Modulation of chemical synaptic transmission 6 6.63e−5 9.95e−5
 Process in the postsynapse 8 1.23e−4 1.68e−4
 Synaptic vesicle exocytosis 5 3.02e−4 3.78e−4
 Regulation of postsynaptic membrane neurotransmitter receptor levels 5 1.55e−3 1.79e−3
 Regulation of postsynaptic neurotransmitter receptor endocytosis 3 1.69e−3 1.81e−3
 Synaptic vesicle endocytosis 3 7.68e−3 7.68e−3
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as well as with antibodies against oligomeric tau (data 
not shown); many tau inclusions were also ubiquitinated.
Gallyas staining in this case showed the same changes as 
those seen in GGT linked to MAPT P301T mutation. Particular 
features in this case were numerous Gallyas-positive threads 
in the cerebral cortex and bizarre globular inclusions in addi-
tion to GOIs. GAIs were Gallyas-negative, but astrocytes with 
perinuclear Gallyas-positive small granular inclusions were 
seldom observed (Supplementary Fig. 5).
Expression of proteins related to astrocytes 
and oligodendrocytes in sGGT and GGT linked 
to MAPT K317M mutation
Only the expression of a few proteins was analysed in the 
frontal cortex in these cases due to the limited availability 
of samples.
In sGGT, AQ4 immunoreactivity was reduced when com-
pared with controls, excepting AQ4 preservation around 
blood vessels. GLUC-t was decreased in the neuropil (Sup-
plementary Fig. 6).
In GGT linked to MAPT K317M mutation, GLUC-t, 
GLT1, and AQ4 immunoreactivity was reduced in the neu-
ropil when compared with controls (Supplementary Fig.  6).
GLUC-t immunoreactivity decorated the capillaries (Sup-
plementary Fig. 6). The number of GLUC-t-immunoreactive 
capillaries per area was significantly increased in sGGT 
36.6 ± 1.36) and GGT linked to MAPT K317M mutation 
(40.4 ± 3.50) when compared with controls (10.92 ± 0.28) 
(p = 0.000).
Biochemical and morphological characteristic 
of sarkosyl‑insoluble fractions of human brain 
homogenates in GGT cases linked to MAPT P301T 
mutation, sGGT, and GGT linked to MAPT K317M
Sarkosyl-insoluble fractions of frontal cortex and subcorti-
cal white matter homogenates from case 1, GGT linked to 
MAPT P301T mutation, when blotted with anti-P-tauSer422 
showed similar band patterns in the frontal cortex and sub-
cortical white matter processed in parallel. Bands of 68 kDa 
and 64 kDa were characteristic of 4Rtaupathy; in addition, 
lower bands of 50 kDa, several bands of about 40 kDa, a 
band of about 35 kDa, and two bands of 25 kDa and 22 kDa 
were seen in the white matter and frontal cortex. The inten-
sity of the bands was higher in the grey matter than in the 
subcortical white matter except for the band of about 35 kDa, 
suggesting minor differences between cerebral cortex and 
underlying white matter regarding tau species. Western blots 
processed with anti-4Rtau antibodies showed a similar band 
pattern from those seen with the anti-P-tauSer422 antibody. 
In contrast, only weak bands of about 55 kDa, 50 kDa, and 
37 kDa were identified with anti-3Rtau antibodies, even used 
at a concentration greater than that used for immunohisto-
chemistry. Importantly, no bands of 64 kDa were obtained 
with this antibody even with long exposure times. Smears 
of molecular weight higher than 75 kDa were noted with 
anti-P-tauSer422 and anti-4Rtau antibodies (Fig. 9). Western 
blots of sarkosyl-insoluble fractions of the frontal cortex 
from GGT linked to MAPT P301T mutation, cases 3 and 4 
stained with anti-P-tauSer422 antibodies, showed two bands 
of 68 kDa and 64 kDa, a doublet of about 50 kDa, weak 
bands or smears of about 40 kDa, one band of about 35 kDa, 
and a faint, almost absent smear of about 25 kDa (Fig. 9).
Sarkosyl-insoluble fractions of frontal cortex homogen-
ates from sGGT case blotted with anti-P-tauSer422 antibod-
ies showed a band pattern very similar to cases 3 and 4, but 
with more precise bands of about 50 kDa and 35 kDa, and 
one lower band of about 20 kDa (Fig. 9).
Western blots of sarkosyl-insoluble fractions of the fron-
tal cortex from GGT linked to MAPT K317M mutation 
showed two bands of 68 kDa and 64 kDa, a smear of about 
60 kDa, smears of about 40 kDa, and, lower down, a weak 
band of about 25 kDa (Fig. 9).
Finally, western blots of sarkosyl-insoluble fractions of 
the frontal cortex from one case of AD stage VI of Braak and 
Braak used as a positive control showed bands of 68 kDa, 
64 kDa, and 60 kDa, lower bands of about 40 kDa and 
35 kDa, and a still lower band of about 25 kDa (Fig. 9).
Mice inoculated with sarkosyl‑insoluble and soluble 
fractions from GGT linked to MAPT P301T mutation
Mice inoculated in the right hippocampus with sarkosyl-
insoluble fractions from the frontal cortex of GGT linked to 
MAPT P301T mutation case 1 at the age of 12 months and 
killed at the age of 18–19 months (n = 4) showed phospho-
tau-immunoreactive cells, as revealed with the AT8 anti-
body, in ipsilateral neurons of the CA1 region of the hip-
pocampus and dentate gyrus, and in glial cells, dots and 
threads in the fimbria and corpus callosum (Fig. 10a–c).
Three mice inoculated in the right hippocampus with 
sarkosyl-insoluble fractions from the white matter of the 
same GGT case at the age of 7 months and killed at the age 
of 14 months showed similar deposits to those observed fol-
lowing inoculation of frontal cortex homogenates. However, 
no deposits were identified in one mouse (data not shown).
Mice inoculated in the right corpus callosum at the age 
of 7 months and killed at the age of 11 months (survival 
4 months) showed phospho-tau-immunoreactive deposits 
along the ipsilateral and middle region of corpus callosum 
in glial cells, threads, and dots. Following inoculation into 
the right corpus callosum in three mice aged 12 months and 
killed 6–7 months later, large numbers of glial cells, threads, 
and dots were identified in the ipsilateral, middle region, and 
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contralateral corpus callosum with antibodies AT8 and anti-
4Rtau. Dots and threads were also stained with anti-3Rtau 
and MC-1 antibodies. Tau-C3 and tau-22 immunostaining 
was negative (Fig. 10d–i). Ubiquitin and p62 were negative 
except for a few ubiquitin dots in the proximal corpus cal-
losum. One mouse inoculated in the corpus callosum did not 
show tau deposits.
PLP1 immunohistochemistry revealed decreased immu-
noreactivity and the presence of small PLP1-immunoreac-
tive dots in the ipsilateral corpus callosum at 4 and 7 months 
following inoculation of GGT sarkosyl-insoluble fractions 
into the corpus callosum (Fig. 10j–l).
Finally, inoculation of GGT sarkosyl-insoluble frac-
tions into the right caudate/putamen (CPu) in mice aged 
10 months and killed five months later showed phospho-
tau deposits, as revealed with AT8 antibody in neurons and 
glial cells, and in threads in the local fibre bundles which 
form the stripes (Fig. 10m–o). In contrast to injection into 
the hippocampus and corpus callosum, inoculation into the 
right CPu produced more restricted spreading. Phospho-tau 
immunoreactivity was present only in the vicinity of the site 
of injection. A few immunoreactive fibres were seen in the 
internal capsule and in the corpus callosum, probably related 
to the diffusion of the inoculum at the time of injection.
Apoptosis, as assessed with the method of in situ end-
labelling of nuclear DNA fragmentation, was not seen in 
inoculated mice at the time-points examined in the present 
study. Reactive astrogliosis and microgliosis, as revealed 
with anti-GFAP and Iba1 antibodies, respectively, were 
absent.
Mice inoculated with sarkosyl-soluble fractions and the 
mouse inoculated with vehicle alone did not show phospho-
tau-immunoreactive deposits (data not shown).
The type of phospho-tau-immunolabelled cells follow-
ing inoculation of sarkosyl-insoluble fractions was recog-
nized by double-labelling immunofluorescence and confocal 
microscopy with anti-tau antibodies and specific neuronal 
(NeuN), astroglial (GFAP), oligodendroglial (Olig2), and 
microglial (Iba1) antibody markers. This procedure identi-
fied NeuN and P-tauThr181 co-localization in neurons in 
the hippocampus in mice subjected to inoculation in the 
hippocampus (data not shown). Oligodendroglial cells, as 
revealed with the Olig2 and AT8 antibodies, were the only 
population of tau-containing glial cells in the fimbria and 
corpus callosum at 6–7 months following inoculation of 
sarkosyl-insoluble fractions in the hippocampus and corpus 
callosum (Fig. 11a–c). Quantitative studies were carried out 
in mice inoculated in the corpus callosum with sarkosyl-
insoluble fractions and killed at 6–7 months after injection, 
in sections processed for double-labelling immunofluo-
rescence and confocal microscopy. Counts revealed that 
about 30% of the total number of oligodendrocytes in the 
ipsilateral corpus callosum contained phospho-tau depos-
its in mice inoculated with GGT homogenates. In no case 
did phospho-tau deposits have the appearance of GOIs as 
seen in human cases. Rather, oligodendroglial inclusions 
had coma-like (coiled bodies) or perinuclear circular mor-
phology. Double-labelling immunofluorescence and confo-
cal microscopy disclosed no differences in the expression 
of H3K12ac and H4K12ac in glial cells with and without 
phospho-tau deposits following inoculation into the corpus 
callosum (Fig. 11d, e). Finally, double-labelling immuno-
fluorescence with phosphorylated-p38 and AT8 antibodies 
revealed co-localization in about 20% of glial cells contain-
ing phospho-tau in the corpus callosum (Fig. 11f).
Gallyas staining showed negative or, very rarely, faint 
positive neurons in the hippocampus, and Gallyas-positive 
coiled bodies in the white matter (Supplementary Fig. 5).
Mice inoculated with sarkosyl‑insoluble and soluble 
fractions from sporadic GGT and familial GGT linked 
to MAPT K317M mutation
WT mice inoculated in the right hippocampus and corpus 
callosum with sarkosyl-insoluble fractions from sGGT and 
GGT linked to MAPT K317M mutation showed the same 
profile as those inoculated with sarkosyl-insoluble fractions 
from GGT cases linked to MAPT P301T mutation. Mice 
inoculated in the hippocampus at the age of 3–4 months and 
killed 6 months later showed phospho-tau deposits in neu-
rons of the hippocampus and dentate gyrus, and glial cells 
in the hilus and fimbria, together with glial cells, threads, 
and dots in the ipsilateral, middle region, and contralat-
eral corpus callosum. Tau deposits in neurons were char-
acterized by small cytoplasmic granules often extending 
to the apical dendrites. Phospho-tau deposits in glial cells 
were perinuclear, often elongated or forming coiled bod-
ies (Fig. 12). GGIs were not observed. Double-labelling 
Fig. 8  Representative neuropathological alterations in GGT linked 
to MAPT K317M mutation. Phosphorylated tau deposition identi-
fied with the antibody AT8 is found in different types of neurons and 
glial cells in various regions including frontal cortex (FC), and frontal 
cortex white matter (FWM), temporal cortex (TC) and white matter 
(TCWM), motor cortex (MC), thalamus (Thal), hypothalamus (Hypo-
thal), putamen (Put), internal capsule (int cap), motor nucleus of the 
vagus nerve (MNVG), and anterior horn of the spinal cord (SC) of 
one affected brother. Neuronal deposits form small granules in the 
cytoplasm (a, o), dense inclusions (d, m), globose tangles (g, o), 
and skein-like inclusions in the motor nuclei of the brainstem (l) and 
motor neurons of the spinal cord (m–o) (black thin arrows). Astro-
glial inclusions are GAIs of variable morphology including astrocytes 
with perikaryal globular inclusions (black thick arrows) (b, d, g, i), 
astrocytes with longer processes (h, j) (white short arrows), and astro-
cytic plaque-like structures (asterisks) (a, e). Oligodendroglial inclu-
sions are GOIs and coiled bodies (c, f, k). Paraffin sections processed 
for immunohistochemistry slightly counterstained with haematoxylin, 
bar = 40 μm
◂
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immunofluorescence using specific glial cell markers iden-
tified oligodendroglial cells as the only glia containing 
phospho-tau deposits.
Neurons were Gallyas-negative and coiled bodies 
Gallyas-positive. Further details were recognized using dou-
ble-labelling immunofluorescence and confocal microscopy 
in mice inoculated with sarkosyl-insoluble fractions from 
GGT linked to MAPT K317M mutation. Most oligodendro-
glial inclusions were coiled bodies, but a minority showed 
bizarre cytoplasmic tau-positive inclusions and, very rarely, 
a tau-positive globular-like appendix in the cytoplasm (Sup-
plementary Fig. 7).
Comparison of tau deposits in human GGT 
and GGT‑inoculated WT mice
The main aspects were the following: (1) neuronal tau 
inclusions in GGT cases were tangles and pretangles, 
whereas phospho-tau deposits in inoculated mice had 
the characteristics of pretangles; (2) tau deposits in GGT 
cases were phosphorylated, had abnormal conformation 
and truncation at aspartic acid 421, contained oligomeric 
tau, and were overwhelmingly composed of 4Rtau. In con-
trast, phospho-tau deposits in inoculated mice did not con-
tain truncated tau and oligomeric tau and were composed 
of 4Rtau and 3Rtau; (3) phospho-tau deposits in GGT 
involved neurons, astrocytes (GAIs), oligodendrocytes 
(GOIs and coiled bodies), and threads; tau inoculation 
in mice involved neurons and oligodendrocytes (coiled 
bodies) in addition to threads; GOIs and GAIs were not 
Fig. 9  Gel electrophoresis and western blotting of sarkosyl-insoluble 
fractions from the frontal cortex (FC) and subcortical frontal white 
matter (WM) in GGT cases linked to MAPT P301T, FC in sGGT, and 
FC in GGT linked to MAPT K317M mutations, using P-tauSer422 
(tauP422) antibody. Western blots of the WM and FC in GGT linked 
to MAPT P301T case 1 show two strong bands of 68 kDa and 64 kDa 
and weaker bands of 50  kDa and 40  kDa, in addition to two lower 
bands of about 25 kDa and 22 kDa. The intensity of a band of 35 kDa 
is higher in the WM when compared with the FC run in parallel. A 
similar band pattern is found with anti-4Rtau antibodies. In contrast, 
a very weak signal, if any, is obtained with the anti-3Rtau antibody. 
Western blots of sarkosyl-insoluble fractions of the frontal cortex 
from GGT linked to MAPT P301T mutation, cases 3 and 4 stained 
with anti-P-tauSer422 antibodies show two bands of 68  kDa and 
64 kDa, a doublet of about 50 kDa, weak bands of about 40 kDa, one 
band of about 35 kDa, and a weak band of about 25 kDa. Sarkosyl-
insoluble fractions of frontal cortex homogenates from sGGT case 
blotted with anti-P-tauSer422 antibodies show bands with a pat-
tern similar to cases 3 and 4, but with more defined bands of about 
45 kDa and 35 kDa, and a lower band of about 20 kDa. Western blots 
of sarkosyl-insoluble fractions of the frontal cortex from GGT linked 
to MAPT K317M mutation show two bands of 68 kDa and 64 kDa, 
a smear of about 60 kDa, smears of about 40 kDa and below, and a 
weak band of about 25 kDa. For comparative purposes, western blots 
of sarkosyl-insoluble fractions of the frontal cortex from one case of 
Alzheimer’s disease stage VI of Braak and Braak show three bands 
of 68  kDa, 64  kDa, and 60  kDa, lower bands of about 45  kDa and 
35 kDa, and one lower band of about 25 kDa
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observed in inoculated mice; (4) similar deposits were 
found in inoculated mice using sarkosyl-insoluble frac-
tions from GGT linked to MAPT P301T mutations, GGT 
linked to MAPT K317M mutation, and sGGT, excepting 
minor particularities in GGT linked to MAPT K317M 
mutation; (5) similar characteristics regarding Gallyas 
staining were seen in GGT cases and inoculated mice; 
and (6) GGT cases had serious damage in the grey matter 
and white matter, a feature which was not reproduced in 
inoculated mice following injection in the hippocampus, 
caudate/putamen, and corpus callosum, excepting loss of 
myelin in the ipsilateral corpus callosum.
Discussion
The present observations are focused on familial GGT 
linked to MAPT P301T mutation with additional studies on 
sporadic GGT and GGT linked to MAPT K317M mutation. 
Clinical and neuropathological alterations in the familial 
GGT cases linked to MAPT P301T mutations are similar 
to those reported in sporadic GGT cases [1]. The clini-
cal manifestations and the distribution and localization of 
pathological changes in the present series differ from one 
case to another among patients bearing the same mutation 
and even among affected members of the same family, as 
previously reported in other tauopathies linked to MAPT 
mutations [10, 28, 38, 42, 47, 112, 135]. GGT linked to 
MAPT P301T mutation cases 2, 3, and 4 is tentatively cat-
egorized as subtype II, case 1 as subtype III; the case of 
sGGT is classified as subtype I, and the GGT case linked 
to MAPT K317M mutation to subtype III, following the 
nomenclature proposed in sporadic GGT [1]. However, in 
addition to the basic traits of the three subtypes, several 
morphological particularities of the inclusions are distin-
guished in the different cases. Regarding neurons, globular 
Pick-like inclusions have been considered typical of sub-
type III in sporadic GGT [116], but here similar inclusions 
are observed in cases 2, 3, and 4, classified as subtype 
II. Regarding astrocytes, GAIs with globular perikaryal 
inclusions are most common in subtype III and GAIs with 
large radiating process-like structures are more common 
in subtype II [116]. This also applies in our series. Yet 
GAIs with radiating processes are also seen in case 1 with 
MAPT P301T mutation and in the case with MAPT K317M 
mutation. Immature forms are present in all GGT cases 
in consonance with earlier observations [116]. Finally, 
astrocyte-like plaques occur in familial cases categorized 
as subtype III.
Biochemical profiles also differ from one case to 
another in the present series, independently of the age 
at onset, gender and duration of the disease. The basic 
two-band pattern, as revealed by western blotting with 
anti-P-tauSer422 antibodies, of 68 kDa and 64 kDa char-
acteristic of 4Rtau tauopathies, already reported in other 
cases suffering from GGT [3, 7, 28, 38, 45, 111, 135], is 
regular in all cases. However, regarding tau species, the 
band patterns of phosphorylated tau differ from one case 
to another in the same cortical region (frontal cortex area 
8) even in cases carrying the same mutation. The profile of 
case 1 linked to MAPT P301T mutation is subtly alike the 
profiles of cases 3 and 4 carrying the same mutation. This 
is manifested in the intensity of bands of about 50 kDa 
which are better defined in cases 3 and 4, and the bands 
of about 40 kDa which are stronger in case 1. The bands 
of truncated phospho-tau at carboxy terminal (bands of 
about 25 and 20 kDa) are almost absent in cases 3 and 4. 
This last characteristic is consistent with the presence of  
Tau-C3 (which recognizes tau truncated at aspartic acid 
421) in case 1 and the almost total absence of tau-C3 with 
immunohistochemistry in cases 3 and 4.
The band pattern in sGGT is similar to that seen in 
cases 3 and 4 bearing the MAPT P301T mutation; in 
accordance, Tau-C3 immunoreactivity is restricted to a 
subpopulation of oligodendroglial inclusions. The study of 
bands by western blotting in GGT linked to MAPT K317M 
mutation is suboptimal due to the poor preservation of 
the sample, as suggested by the appearance of smears 
below the two bands of 68 kDa and 64 kDa, particularly 
below 50 kDa. Yet the band of about 25 kDa is visible in 
agreement with the presence of Tau-C3-immunoreactive 
inclusions in tissue sections. Oligomeric bands are more 
marked in case 1 when compared with the other cases.
Finally, differences between the frontal cortex and 
immediate subcortical white matter are also seen, at least 
in case 1, the only one assessed. The intensity of bands 
is lower in the white matter excepting one band below 
37 kDa, the intensity of which is lower in the cerebral 
cortex.
The biochemical profile of phospho-tau in GGT cases 
differs from that seen in corticobasal degeneration (CBD) 
and progressive supranuclear palsy (PSP). On immunoblots 
of sarkosyl-insoluble brain extracts, a 33 kDa band predomi-
nates in the low molecular weight tau fragments in PSP, 
whereas two closely related bands of approximately 37 kDa 
predominate in CBD [5, 117]. The patterns described in PSP 
and CBD appear to be identical from one patient to another. 
However, our observations in GGT show, in addition, cer-
tain individual variability in GGT. Considering the clinical 
and neuropathological variability of PSP, Richardson’s syn-
drome, and CBD, whether individual variabilities occur in 
CBD and PSP deserves further study.
The site of mutation in the pathogenesis of familial GGT 
does not shed light on the particular phenotype in familial 
cases, as mutations causative of familial GGT are linked to 
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exon 10, exon 11, exon 1, and to IVS10 + 16 [10, 44, 56, 
62, 111, 112, 135]. The small number of reported cases of 
familial GGT makes it difficult to ascribe individual changes 
to the different mutations in MAPT, as suggested by some 
researchers [110, 111]. It is more likely the case that familial 
GGT, like sporadic GGT, is subjected to currently unknown 
biochemical factors which demarcate individual-specific 
phenotypes independently of the genetic defect. Based on 
newly available information, the classification of GGT into 
different subtypes proposed a few years ago [1] should be 
interpreted with caution and viewed as an instrumental cat-
egorization subjected to refinement [11]. Further studies are 
needed to better understand cellular and regional vulnerabil-
ity in frontotemporal tauopathies [43].
Astrocytopathy and oligodendrocytopathy in GGT 
Most neurodegenerative diseases with abnormal protein 
aggregates can no longer be viewed solely as neuronopa-
thies. Abnormalities in astrocytes and oligodendrocytes 
imply key roles for glial cells in distinct neurological dis-
eases. Astrocytopathy and oligodendrogliopathy have 
emerged as main components of neurodegenerative diseases 
with abnormal protein aggregates [8, 29, 30, 33–35, 60, 86, 
94, 97, 99, 103, 123–125, 129, 132].
Alterations of astrocytes and oligodendrocytes in GGT 
are barely known except for the description of characteristic 
morphology of GAIs and GOIs, including Gallyas-negative 
GAIs, and Gallyas-positive GOIs and coiled bodies [33, 34, 
67]. For this reason, the levels of gene transcripts of astro-
cytes and oligodendrocytes are assessed separately in the 
frontal cortex and subcortical frontal white matter in familial 
GGT carrying the MAPT P301T mutation. Despite the limi-
tations inherent in the small number of pathological samples, 
mRNA expression of basal, reactive, and inflammatory 
markers of astrocytes (ALDH1L1, GFAP, YKL40, respec-
tively) is increased in the frontal cortex in GGT. GJA1 cod-
ing for gap junction α1-protein/connexin-43, the major con-
stituent of gap junctions in astrocytes, is also significantly 
increased, thus supporting the idea of an extended astrocytic 
network in GGT which would facilitate, at least in normal 
conditions, the transfer of small molecules and metabolites 
such as glucose and lactate [48, 52, 91]. Whether those gap-
mediated functions are at work in GGT is not known.
The present findings show reactive astrocytosis character-
ized by increased GFAP and YKL40. Increased chaperone 
responses manifested as increased αB-crystallin expression 
in glial cells are also independent of the intracytoplasmic tau 
inclusions, as already reported in astrocytes in other tauopa-
thies [21, 85]. Yet GFAP is redistributed in the cytoplasm 
of astrocytes containing tau, a feature also found in other 
tauopathies with tau deposits in astrocytes [33, 37]. Astro-
cytopathy in GGT linked to MAPT P301T mutation is also 
manifested by increased AQ4 expression, decreased GLT1, 
decreased GLUC-t, and altered MPC1 and UCP5, arguing 
for impaired modulation of water, glutamate, and glucose 
transport, and altered mitochondrial coupling, in affected 
astrocytes.
Immunohistochemistry in case 1 discloses that sev-
eral mRNA alterations are in the same line as those of the 
expression of corresponding proteins (for example, increased 
expression of GFAP and YKL40 proteins), and it identi-
fies additional protein alterations in astrocytes in GGT not 
detected at the mRNA level by RT-qPCR. Some of these 
alterations are particularly informative by alerting to abnor-
mal function of GGT astrocytes. Aquaporin 4 (AQ4) immu-
noreactivity is markedly increased in the frontal cortex, sug-
gesting abnormalities in water transport between astrocytes 
and blood vessels. Alterations in AQ4 expression have been 
reported in age-related tau astrogliopathy (ARTAG) [37, 
71], in astrocytes surrounding β-amyloid plaques, and in 
perivascular astrocytes in AD [60]; reactive astrocytes in 
bovine spongiform encephalopathy and related models, in 
which reactive astrocytes do not contain hyper-phosphoryl-
ated tau and  PrPSC, respectively, also express high levels of 
AQ4 [18]. Similarly, altered expression of astrocytic and 
oligodendroglial connexins is common in many neurodegen-
erative diseases independently of the presence of abnormal 
protein deposits in reactive cells [19, 89, 90, 126]. Therefore, 
altered AQ4 expression and increased connexin-43 immu-
noreactivity cannot be considered markers of a particular 
disease.
Glutamate transporter 1 immunoreactivity is markedly 
reduced, in spite of the larger number of astrocytes, in GGT 
linked to MAPT P301T mutation, thus suggesting impaired 
glutamate transport in this disease, leading in turn to 
increase glutamate excitotoxicity and neuron damage [101]. 
Fig. 10  Phospho-tau deposits in neurons of the hippocampus (a, b) 
and in glial cells, threads, and dots in the fimbria (c) following unilat-
eral inoculation of sarkosyl-insoluble fractions from the frontal cortex 
of GGT linked to MAPT P301T mutation into the right hippocampus 
of WT mice aged 12 months and killed 6 months later. Phospho-tau 
deposits are also seen in glial cells, threads, and dots in the ipsilateral 
(d), middle region (e), and contralateral corpus callosum (f) in mice 
inoculated at the age of 12 months and killed at the age of 18 months. 
Deposits are immunostained with antibodies MC-1 and anti-4Rtau (g, 
h). Some deposits are also identified with antibodies against 3Rtau 
(i). j–l PLP1 immunohistochemistry reveals reduced intensity and the 
presence of small PLP1-immunoreactive dots (arrows) in the corpus 
callosum in mice after 4 and 7 months following unilateral inocula-
tion of sarkosyl-insoluble fractions from GGT linked to MAPT P301T 
mutation when compared with controls. m–o Phospho-tau deposits 
in the CPu following unilateral inoculation in the right caudate/puta-
men in mice aged 10 months and killed 5 months later; deposits are 
found in neurons, glial cells, and numerous threads in the stripes. hip 
hippocampus, fimb fimbria, call ipsi middle, contralat corpus callo-
sum ipsilateral, middle region and contralateral, call corpus callosum, 
CPu caudate/putamen. Paraffin sections processed for immunohisto-
chemistry slightly counterstained with haematoxylin, bar = 50 μm
◂
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Fig. 11  a–c Double-labelling immunofluorescence and confocal 
microscopy to NeuN, Olig2, and GFAP, and phospho-tau specific 
antibodies P-tauThr181, and AT8, respectively, in the fimbria (a) and 
corpus callosum (b, c) of WT mice injected with sarkosyl-insoluble 
fractions from GGT linked to MAPT P301T mutation into the hip-
pocampus at the age of 12 months and killed at the age of 18 months. 
Phospho-tau inclusions are observed only in oligodendrocytes 
(arrows). Tau deposits do not co-localize with neuronal and astro-
cytic markers (asterisk). d Double-labelling immunofluorescence to 
H3K9me2 and P-tauThr181, and e double-labelling to H4K12ac and 
phospho-tau AT8 in the corpus callosum of WT mice inoculated with 
sarkosyl-insoluble fractions of GGT linked to MAPT P301T muta-
tion, showing histone modifications expressed equally in cells with 
(thin arrows) and without hyper-phosphorylated tau deposits (d, e). 
Histone H4 (acetyl K12) immunoreactivity is expressed equally in 
oligodendrocytes with coiled bodies (thin arrows) and oligodendro-
glia without tau inclusions. f Phosphorylated p38 Thr180-Tyr182 
(p38P) co-localizes with AT8-immunoreactive deposits (asterisk) in 
glial cells in the corpus callosum of WT mice inoculated with sarko-
syl-insoluble fractions of GGT at the age of 12  months and killed 
at the age 18 of months. Nuclei are counterstained with DRAQ5™ 
(blue). Paraffin sections, a, b, and c bars = 20 μm, 24 μm and 30 μm; 
d, e, and f bars = 10 μm, 30 μm, and 20 μm, respectively
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Abnormal glutamate transport is well documented in a lim-
ited number of neurological diseases, most specifically in 
amyotrophic lateral sclerosis. Abnormal glutamate transport 
function has also been reported in mutant amyloid precur-
sor protein transgenic mice [87], and altered ratio between 
GFAP and GLT1 in the cerebral cortex in AD [107]. How-
ever, we were unable to find differences in the total expres-
sion levels of GLT1 in AD and in dementia with Lewy 
bodies using the same methods as those used in the present 
study [46]. GLT1 (EAAT2) expression is markedly reduced 
in most astrocytes bearing hyper-phosphorylated tau in a 
rare familial behavioural variant of frontotemporal dementia 
associated with astrocyte-predominant tauopathy not linked 
to mutations in MAPT [39]. Reduced GLT1 expression also 
occurs in transgenic mice selectively expressing abnormal 
hyper-phosphorylated tau in astrocytes [20]. Therefore, 
abnormal GLT1 expression appears to be a major defect in 
GGT linked to MAPT P301T mutation.
The expression of proteins involved in glucose transport 
is also abnormal in GGT linked to MAPT P301T mutation: 
GLUC-t encoded by the solute carrier family 2, member 1 
(SLC2A1) is reduced in the neuropil. Mitochondrial pyruvate 
carrier 1 (MPC1) immunoreactivity is decreased in neurons 
in the frontal cortex (in line with results of mRNA expres-
sion), but MPC1 is markedly increased in astrocytes in the 
subcortical white matter (in contrast to mRNA expression 
Fig. 12  a–f WT mice inoculated unilaterally into the right hippocam-
pus and corpus callosum with sarkosyl-insoluble fractions from 
sGGT at the age of 3 months and killed at the age of 9 months. Phos-
phorylated tau deposits are seen in neurons of the hippocampus (b, 
c), glial cells in the hilus of the dentate gyrus (a); variegated cells, 
threads and dots in the fimbria (d); and glial cells, threads and dots 
in the ipsilateral (e) and contralateral (f) corpus callosum. g–i WT 
mice inoculated into the right hippocampus and corpus callosum 
with sarkosyl-insoluble fractions from GGT linked to MAPT K317M 
mutation at the age of 4 months and killed at the age of 10 months. 
Phosphorylated tau deposits are seen in one neuron of the hippocam-
pus (g) and in glial cells, threads and dots in the middle region (h), 
and contralateral (i) corpus callosum. Tau deposits in neurons are 
characterized by small cytoplasmic granules often expanding to the 
apical dendrites. Tau deposits in glial cells are perinuclear, often 
elongated or forming coiled bodies. GGIs are not observed. hip hip-
pocampus, fimb fimbria, dent gyr dentate gyrus, call ipsi middle, con-
tralat corpus callosum ipsilateral, middle region, and contralateral. 
Paraffin sections processed for immunohistochemistry slightly coun-
terstained with haematoxylin, bar = 50 μm
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levels in the same region). Double-labelling immuno-
fluorescence and confocal microscopy disclose no differ-
ences in MPC1 and UCP4 immunoreactivity in cells with 
and without tau deposits, indicating that decreased MPC1 
immunoreactivity in frontal cortex is not linked to coexisting 
deposition of hyper-phosphorylated tau in the same cells. 
In contrast, UCP5 immunoreactivity is decreased only in 
cells containing phospho-tau aggregates when compared 
with similar cells without phospho-tau deposits in the same 
tissue sections.
Regarding white matter, OLIG1 and OLIG2 mRNA 
expression levels are significantly reduced in GGT cases 
linked to MAPT P301T mutation compared to controls. This 
is accompanied by a significant decrease in the expression 
of all assessed genes involved in myelin formation, includ-
ing MBP, PLP1, CNP, MAG, MAL, MOG, and MOBP. 
Immunohistochemistry further demonstrates the reduction 
of CNPase, MBP, and PLP-1 proteins in the white matter in 
GGT. The mRNA expression of SLC2A1, coding for solute 
carrier family 2 (facilitated glucose transporter), member 1, 
and MCT1 coding for the solute carrier family 16 (monocar-
boxylic acid transporter), member 1 is significantly reduced 
in GGT when compared with controls. White matter abnor-
malities have been described in transgenic mice bearing 
human tau mutations in which neurons, astrocytes, and oli-
godendrocytes accumulate filamentous inclusions [80, 81]. 
More telling is the observation that selective over-expression 
of mutant tau in oligodendrocytes using CNP promoter in 
mice produces filamentous inclusions in oligodendrocytes, 
and progressive impairment of axonal transport followed by 
myelin and axonal disruption [58].
In light of the evidence, we can consider that, in addition 
to impaired white matter connectivity due to tau deposits in 
neurons and threads, oligodendrocytopathy is a key factor in 
the pathogenesis of GGT linked to MAPT P301T mutation, 
not only because of the presence of phospho-tau deposits 
conforming GOIs and coiled bodies, but more importantly 
because these deposits have consequences in oligodendro-
cyte function, leading to defective myelin synthesis, demy-
elination, oligodendroglial energy metabolism dysfunction, 
and concomitant axonal damage manifested as disrupted 
axons, and axonal varicosities and spheroids filled with 
phosphorylated H neurofilaments.
Only the expression of a few proteins was analysed in the 
frontal cortex in sGGT and in GGT linked to MAPT K317M 
mutation due to the limited availability of tissue. YKL40 
immunoreactivity is markedly increased in GGT linked to 
MAPT K317M mutation. GLUC-t and GLT1 immunoreac-
tivity is markedly reduced in the neuropil in sGGT and GGT 
linked to MAPT K317M mutation. These aspects are similar 
to those seen in the cases of GGT linked to MAPT P301T 
mutation. Regarding AQ4, it is preserved around blood ves-
sels in sGGT and reduced in frontal cortex in MAPT linked 
to MAPT K317M mutation. The reason of differences in 
AQ4 expression between GGT linked to MAPT P301T muta-
tion, and sGGT and MAPT linked to K317M mutation, can-
not be explored in detail because of the small number of 
cases.
The question of increased numbers of capillaries in the 
frontal cortex in GGT has not been previously addressed. 
The number of capillaries in the frontal cortex, as revealed 
with GLUC-t immunohistochemistry, is significantly 
increased in all GGT cases when compared with controls in 
the present series. Our hypothesis is that this effect is due to 
the neuronal loss and cortical atrophy of frontal degeneration 
in GGT cases, together with angiogenesis (capillary sprout-
ing) induced by protein pathology and neuroinflammation, 
as proposed in ageing and other brain diseases [93].
GGT: not only hyper‑phosphorylated tau in neurons 
and glial cells
In addition to hallmark pathological features specific for 
every particular neurodegenerative disease, the use of 
combined “omics” has delineated a more complex profile 
involving a large number of altered expression profiles of 
proteins and metabolites, and altered biochemical pathways 
in the majority of neurodegenerative diseases with abnor-
mal protein aggregates [73–75]. Some of these have been 
identified at early stages of the disease without apparent con-
nection with the localization of pathogenic protein aggre-
gates [32]. Knowledge of these alterations indicates that the 
occurrence of protein aggregates is not the only alteration 
in the brain of affected individuals. Phosphoproteomics 
has identified hyper-phosphorylation of a large number of 
unrelated proteins in AD [12, 22, 24, 77, 113, 115, 121, 
134] and ARTAG [37]. Based on these observations, we 
hypothesized that widespread phosphorylation changes, as 
identified in AD and ARTAG, may occur in other tauopa-
thies such as GGT. Our structure-resolved analysis of the 
proteomic and phosphoproteomic changes that occur in 
familial GGT linked to MAPT P301T mutation reveals that 
the perturbed proteostasis is more evident in frontal cortex 
than in white matter. Functional annotation shows that 55% 
of differential phosphosites detected in frontal cortex are 
located on proteins involved in neuron projection morpho-
genesis and chemical synaptic transmission, revealing novel 
phosphorylation-dependent regulatory paradigms for GGT. 
On the other hand, the deregulation of NEFL, NEFH and 
INA protein levels as well as the alteration in the phospho-
rylation state of tau, MAP1A/MAP1B commonly observed 
in frontal cortex and white matter reinforces the disruption 
of the neuronal cytoskeleton in GGT. Based on the altera-
tion of the steady- or phosphorylation states of predicted 
and verified tau interactors such as casein kinase 2 alpha 1, 
O-linked N-acetylglucosamine (GlcNAc) transferase, S100 
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calcium binding protein B, Rho/Rac guanine nucleotide 
exchange factor 2, ubiquitin C, and microtubule-associated 
protein 2 (CSNK2A1, OGT, S100B, ARHGEF2, UBC, and 
MAP2, respectively) (Supplementary Table 6; Supplemen-
tary Fig. 4), our data point up potential fluctuations of the 
tau interactome in both brain areas, yielding new insights 
into the pathophysiological role of tau in GGT. Although our 
study uncovers many intricacies in frontal cortex and white 
matter molecular homeostasis in GGT, there are potential 
limitations to our prototyping study that warrant discussion. 
First, due to technological issues, we failed to accurately 
quantify many (phospho)proteins expressed at low levels 
that might also participate in the GGT phenotype. Second, 
although our mass-spectrometry approach revealed changes 
in the phosphorylation profile of tau protein in both regions, 
the detected phosphorylated sequences are common to the 
six tau isoforms expressed in human brain, hampering une-
quivocal assignment. Third, our results are limited by protein 
abundance averaging among multiple cell layers, hampering 
the exploration of cell-type specific molecular alterations.
Together, these observations reveal GGT to be linked to 
MAPT P301T mutation as a disorder of protein phosphoryla-
tion affecting different substrates and not only protein tau.
Seeding and spreading of GGT tau 
following intra‑cerebral inoculation in WT mice
Phospho-tau seeding and spreading occurs following inoc-
ulation of preformed synthetic tau fibrils [61], and injec-
tion of fibrillar-enriched fractions from human or mouse 
brain homogenates of tauopathies, including AD, only tan-
gle dementia, argyrophilic grain disease, PSP, and CBD, 
injected into the brain of transgenic mice expressing 4R 
human tau or human mutant tau [2, 9, 14–16]. Abnormal 
tau deposits are generated in neurons related to connectivity 
rather than to proximity [2]. Deposits in glial cells appear 
to have disease-dependent morphology in inoculated trans-
genic mice expressing 4R human tau or mutant human tau 
[9, 14–16].
Similar inoculations carried out in WT mice have shown 
few neuronal, oligodendroglial, or thread inclusions regard-
less of the origin of the inclusions [14]. Other studies have 
reported only neurons and threads as targets of tau seeding 
following inoculation of AD homogenates, but neurons and 
glial cells, reminiscent of astrocytic plaques and tufted astro-
cytes, following inoculation of tau obtained from CBD and 
PSP brain homogenates, respectively [54, 92]. Another set 
of experiments described grains and threads but not deposits 
in neurons and glial cells following inoculation of paired 
helical filaments from AD cases in the brain of WT mice 
[6]. Our previous studies have shown a rather homogeneous 
pattern of tau seeding and spreading following inoculation of 
sarkosyl-insoluble fractions into the hippocampus or into the 
corpus callosum of WT mice, independently of the tauopa-
thy. Nerve fibres and coiled bodies were the only tau depos-
its in the corpus callosum following inoculation of homoge-
nates from AD, primary age-related tauopathy (PART), 
ARTAG, GGT, PSP, Pick’s disease (PiD), and frontotem-
poral lobar degeneration linked to MAPT P301L mutation 
(FTLD-P301L) [36]. Neurons and oligodendrocytes were 
the main targets following inoculation of sarkosyl-insoluble 
fractions of AD, PART, and ARTAG into the hippocam-
pus of WT mice [37, 41]. No GAIs, GOIs, or thorn-shaped 
astrocytes (characteristic of ARTAG) were seen following 
inoculation of GGT and ARTAG, respectively.
The present findings following unilateral inoculation of 
sarkosyl-insoluble fractions of GGT into the hippocam-
pus, together with the observations of previous studies, 
are consistent with the idea that tau can be transmitted 
trans-synaptically from one neuron to another neuron, and 
that this mechanism has implications in the progression of 
abnormal tau deposits in tauopathies [27, 49, 50, 79, 83, 
106]. Seeding and spreading along neuronal connections 
following intracellular injection of tau synthetic preformed 
fibrils is accompanied by altered synaptic transmission, 
motor deficits, and abnormal behaviour [109].
Trans-synaptic transmission is certainly not the mecha-
nism leading to the spreading of phospho-tau in oligo-
dendrocytes. Since phospho-tau-containing oligodendro-
cytes are associated with abnormal tau accumulation along 
tracts, it may be inferred that tau-containing oligodendro-
cytes are bystanders linked to phospho-tau deposition in 
axons. However, phospho-tau deposition in oligodendro-
cytes may be not merely a passive phenomenon, as active 
phospho-p38 kinase expression co-localizes in oligoden-
drocytes containing tau, thus suggesting active tau phos-
phorylation [31, 98]. Several lines of evidence support this 
interpretation. Endogenous mouse tau is deposited in oli-
godendrocytes in mice expressing transgenic human tau, in 
a way that makes it evident that mouse tau has the capacity 
to be recruited and aggregated in oligodendrocytes [100]. 
Similarly, sarkosyl-insoluble fractions containing abnor-
mal tau can recruit endogenous murine tau in the present 
paradigm using GGT homogenates. The transmission of 
phospho-tau along oligodendrocytes may be explained 
by other mechanisms, particularly when referring to long 
tracts, as in the corpus callosum, where oligodendrocytes 
are the main cellular population [133], and the only cell 
type containing phospho-tau in our model. Alternative 
mechanisms proposed in cellular models include tau 
release using ectosomes or exosomes, freely released to 
the extracellular space, and uptake through endocytosis 
and receptor-mediated endocytosis, tunneling nanotubues, 
and use of extracellular vesicles as shuttles [23, 26, 50, 
51, 53, 59, 76, 79, 118, 127, 128, 130, 131]. Deposition 
of phospho-tau in oligodendrocytes has consequences, as 
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decreased PLP-1 immunoreactivity and small PLP1-immu-
noreactive dots appear in the proximal corpus callosum 
following inoculation of GGT sarkosyl-insoluble fractions, 
suggesting damage to the white matter.
Epigenetic changes may regulate gene transcription. 
Previous studies showed that expression of dimethylated 
histone H3K9 (H3K9me2) and acetylated histone H3K12 
(H3K12ac), which regulate rRNA transcription [17, 114], 
decreased in AD with disease progression [57]. However, 
no differences in the expression of these histones were seen 
in GGT cases or in tau-containing neurons and glial cells in 
inoculated mice with sarkosyl-insoluble fractions of human 
GGT homogenates. These negative results do not rule out 
the possibility of epigenetic regulation of active pathways 
linked to tau phosphorylation and other metabolic alterations 
linked to tau seeding in recruited target cells.
Finally, it is important to stress that the tau biosen-
sor cell line expressing human tau exposed to sporadic 
or mutant GGT brain lysates reveals large deposits remi-
niscent of globular inclusions in GGT [13]. However, no 
GAIs or GOIs, but only coiled bodies, are regularly seen 
in WT mice inoculated with sarkosyl-insoluble fractions 
of GGT linked to MAPT P301T mutation, sGGT, and GGT 
linked to MAPT K317M mutation in our study. The excep-
tion of a few bizarre oligodendroglial inclusions following 
inoculation of homogenates from MAPT K317M samples 
does not detract from the general concept that coiled bod-
ies are the characteristic oligodendroglial phospho-tau 
inclusions in WT mice inoculated with homogenates 
from GGT and other tauopathies [36, 37, 41]. This sug-
gests that host tau is crucial to recapitulate typical inclu-
sions in human diseases. In this line, murine tau differs 
from human tau in several aspects including the predomi-
nance of 4Rtau in adulthood, the C-terminal domain, the 
N-terminal domain, binding sites, and distribution and 
localization of the different tau isoforms [64, 78, 82, 88, 
102, 118]. These differences may account for the species’ 
specificity to tau vulnerability, a feature known as species 
barrier in prion diseases [55, 104]. As a working hypoth-
esis, regional differences in tau may also participate in 
selective regional and cellular vulnerability. Therefore, not 
only tau strains of the donor [25, 122] but also tau strains 
in the host may be critical to refining the characteristics 
of abnormal protein deposits in degenerative diseases with 
abnormal protein aggregates.
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